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1 Introduction 
1.1 Main Project Objectives 
Citizens, policymakers and social scientists often call for citizen participation for reasons of 
democratic legitimacy and effectiveness. A field in which this has been vigorously asserted is 
science and technology policy. Many countries therefore witnessed the introduction of 
Participatory Technology Assessment (PTA). The "litmus test" of PTA and of citizen 
participation, however, is their impact on policy making. But can PTA keep its promises and 
increase the influence of citizens' voices on decision-making? What is in actual fact the 
impact of PTA on decision-making? How can it be increased? 
In order to answer these questions the project "Impact of Citizen Participation on Decision 
Making in a Knowledge Intensive Policy Field" (CIT-PART) comparatively studies the impact 
of PTA and expert based technology assessment (TA) on policy making in Austria, Canada, 
Denmark, Italy, Latvia, The Netherlands, Sweden, Switzerland, United Kingdom, the 
European Commission, the Organization for Economic Co-operation and Development 
(OECD) and the Holy See. From these the project draws conclusions about the possible 
impact of institutionalized citizen participation at European Union (EU) level. 
The project addresses these questions through the reactions of various political systems to 
the challenge of xenotransplantation, which stands for the transplantation of animal organs, 
tissues or cells into humans. Xenotransplantation is highly controversial: its advocates 
perceive it as promising since it could help to remedy the shortage of human transplants, 
while its opponents insist that it involves too many risks - most prominently infection from 
animals to humans - and ethical questions. 
By adopting a theoretical approach of “social practices”, this project starts from the 
assumption that the impact of citizen participation on decision-making is not only dependent 
on the quality of the PTA process itself but on practices of policymaking in which PTA is 
embedded. Following from this theoretical approach, the project applies qualitative methods 
of empirical research. 
1.2 Case Selection 
Since the mid 1990s the European Institutions and the European Agency for the Evaluation 
of Medicinal Products (EMEA)1 adopted diverse xenotransplantation policies (see Table 1). 
On the one hand they financed and enabled xenotransplantation research through various 
                                                     
1 The European Agency for the Evaluation of Medicinal Products was renamed in 2004 into European Medicines 
Agency (Regulation 726/2004). We will use the unofficial abbreviation EMA for the European Medicines Agency and 
EMEA for the European Agency for the Evaluation of Medicinal Products. 
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measures. The European Commission, e.g., has been funding xenotransplantation research 
since its 4th Framework Programme; in 2001 the European Commission’s Scientific 
Committee on Medicinal Products and Medical Devices (SCMPMD) formulated a cautious 
yet overall positive opinion concerning xenotransplantation; in 2003 the EMEA published 
“Points To Consider On Xenogeneic Cell Therapy Medicinal Products”, addressing firms who 
might plan to apply for market authorization in this area; in 2009 the Scientific Committee on 
Health Environment and Risk (SCHER) adopted its Opinion “The need for non-human 
primates in biomedical research, production and testing of products and devices” (SCHER 
2009), which identified xenotransplantation as one of a few research areas where the use of 
non-human primates was considered necessary. On the other hand, European Institutions 
also contributed to more restrained xenotransplantation policies. In 2001 the European 
Council, the European Parliament and the European Commission agreed on Directive 
2001/20/EC, which enabled European Member States to postpone applications for clinical 
research on xenotransplantation without time limit. All these policies were based on expert 
advice and often explicitly excluded the consideration of social and ethical problems from the 
scope of its analysis. Policy making procedures as well as the procedural arrangements of 
expert committees left little space for citizen participation. However, there is also another 
facet to EU xenotransplantation policies. The European Commission did not only fund 
xenotransplantation research itself but also research into its ethical, legal and social aspects 
(ELSA). Moreover it supported research, which looked into the problem of how to involve 
stakeholders into debates about the ethics of xenotransplantation. This case study aims to 
look more deeply into these varied xenotransplantation policies. 
The topic of public participation is particularly challenging for the European Institutions for 
several reasons. First, similarly to national governments, the European Institutions are highly 
complex bureaucratic organizations, which, as has already  been shown, have to cover a 
wide range of policy fields. They therefore face problems of internal differentiation and 
coordination typical to complex organizations. The complexity of European Institutions, 
however, is significantly amplified because of the various, and to a certain extent contending, 
levels of European policy making (communal, regional, national, and European) and 
European Institutions (European Commission, European Council, and European 
Parliament). This complex relationship is particularly played out in the area of health policy, 
where competencies lie mainly with the European Member States. The case study identifies 
the opportunities for and obstacles to citizen participation in a multilevel system. 
Against this background the main research questions of this case study are: 
• Which xenotransplantation policies did European Institutions and the EMEA/EMA 
develop? 
• Which actors were involved in what practices in the policy making processes? 
• What role did experts and the public play in these processes? 
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In addressing these questions, we focus particularly on xenotransplantation policies around 
the turn of the millennium but will also address some later developments in the first decade 
of this century. 
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Table 1: Timeline and overview of landmark developments 
1997  The European Commission starts funding xenotransplantation research projects. 
1998 02 The SCMPMD mentions xenotransplantation as a subject that will become 
important in the future.  
1999 09 The SCMPMD working group commences its work. 
2000 03 “Life sciences and biotechnology – A strategy for Europe” identifies 
Xenotransplantation as an economically promising area. 
2001 03 Directive 2001/18/EC on the deliberative release into the environment of 
genetically modified organisms is released. 
 04 Directive 2001/20/EC relating to the implementation of good clinical practice in the 
conduct of clinical trials on medicinal products for human use is released. The 
Directive (updated by Directive 2005/28/EC) explicitly addresses the use of 
xenogeneic cell therapy. 
 10 The SCMPMD adopts its Opinion on xenotransplantation. 
 11 Directive 2001/83/EC on the community code relating to medicinal products for 
human use is released.  
2000  The EMEA starts to work on a guidance on xenotransplantation. 
2003 06 Directive 2003/63/EC amending Directive 2001/83/EC establishes regulatory 
oversight on xenotransplantation in the field of medicinal products by including 
xenogeneic cell therapy into its Annex I (Part IV). 
2004 03 Regulation 726/2004 reforms the EMEA and lays down rules for the authorization, 
supervision and pharmacovigilance of medicinal products for human and 
veterinary use. 
 06 The EMA adopts “Points to consider on Xenogeneic Cell Therapy Medicinal 
Products”.  
2007 09 The European Parliament urges the Commission to end the use of apes and wild-
caught monkeys in research and to establish a timeline to replace all non-human 
primates (NHP). 
 09 The Commission responds that using non-human primates is currently necessary 
and requests an Opinion from the European Commission’s Scientific Committee 
on Health and Environmental Risks (SCHER). 
2008 10 Regulation 1394/07 on advanced therapy medicinal products (ATMP) enters into 
force. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) 
adopts a final opinion on the granting, variation, suspension or revocation of a 
marketing authorisation for the medicine concerned.  
2009 01 The SCHER identifies xenotransplantation as an area where the use of NHP is 
necessary. 
2010 01 Guideline on xenogeneic cell-based medicinal products replaces “Points to 
Consider on Xenogeneic Cell-Therapy Medicinal Products”. 
 11 Directive 2010/63/EU acknowledges that animals, including non-human primates, 
are needed for research purposes. 
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1.3 Methods 
This report is based on expert interviews and document analysis. The documents analyzed 
include official documents from, e.g., the European Commission, the European Parliament, 
the European Council, the EMEA/EMA, the SCMPMD and the SCHER. Moreover, the report 
is based on a review of relevant literature on xenotransplantation policies, the European 
Institutions and the EMEA/EMA. The main sources of information were interviews with civil 
servants and researchers active in EU xenotransplantation policies. Interviews were 
conducted with four officials of the European Commission, one xenotransplantation 
researcher, three researchers who participated in various scientific committees advising the 
European Commission, and one scholar of jurisprudence (see 8.4). In addition, a written 
statement by the EMA, which was provided on request, was analyzed. 
Out of the interviews, four were carried out face-to-face and five were conducted by 
telephone. They were based on a guideline shared by all CIT-PART partners, which was 
derived from the methodological guidebook and was adapted according to necessity, 
primarily according to the interviewee’s role in EU xenotransplantation policies. Interviews 
lasted approximately thirty minutes to one hour; almost all of them were taped and fully 
transcribed. Transcripts and records were analyzed by qualitative methods (thematic 
analysis). Interviews were used to describe EU xenotransplantation policies and to examine 
social practices of policy making, technology assessment and citizen participation. In a first 
round of analysis, themes were identified in each interview. In a second round, these themes 
were compared across interviews and theories were synthesized. Thematic analysis was 
conducted with the use of Atlas.ti, a software tool specifically developed for qualitative 
analysis. Interviews are quoted within the text. The letter in brackets refers to the interview 
and the numbers refer to the relevant lines in the transcript. In case of the written statement, 
the number refers to the respective page. 
1.4 Acknowledgements 
We acknowledge the funding of this research project by the European Commission. Without 
this support our research would have been impossible. In addition we want to thank all 
interviewees for their willingness to participate in the project. Without their open support we 
would have been unable to write this report. We also want to thank Vera Akhmetova and 
Hanspeter Wielander for transcription as well as Alexander Lang for transcription as well as 
assistance for additional Internet recherché. 
Authorship of this report is divided in the following way: Anna Pichelstorfer and Karina 
Weitzer did most of the Internet recherché and literature review; they identified interview 
partners and produced an initial draft version of this report. Peter Biegelbauer contributed to 
the chapter on EU policy making and commented on parts of the final report. Erich Griessler 
did additional Internet and literature recherché, carried out and analyzed expert interviews, 
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made the overall concept of the report, extended and deepened analysis and wrote the final 
version of this report. 
1.5 Layout of the Paper 
The paper starts with an analysis of the scientific advice of the SCMPMD to the European 
Commission (chapter 2) and continues with a brief chapter on xenotransplantation as a 
promising economic research area (chapter 3). Chapter 4 describes the development of the 
regulation of xenotransplantation from the Directive on clinical trials to points to be 
considered by potential applicants for market authorization. Chapter 5 focuses on the use of 
non-human primates in research in the context of xenotransplantation. Chapter 6 discusses 
the European Commission’s role in research funding, both in xenotransplantation itself as 
well as in ELSA research and citizen participation. The concluding section (chapter 7) 
recapitulates the main findings by addressing the central research questions of the CIT-
PART project. The Annex provides a timeline of major developments, an overview of the 
political system of the EU and the policy field, as well as lists of references, interviewees and 
abbreviations.  
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2 The SCMPMD 
The European Commission’s Health and Consumer Protection Directorate-General2 was one 
of the first divisions within the Commission to deal with xenotransplantation policies.3 In 
February 1999 the then recently established Scientific Committee on Medicinal Products and 
Medical Devices (SCMPMD) took initiative and brought up the issue as one of several topics 
which might become interesting for its future activities. Later the same year the SCMPMD 
decided to prepare an Opinion on Xenotransplantation. The following section outlines the 
development and content of the Opinion and views this process in the context of the 
reorganisation of the European Commission’s advisory system in health and consumer 
protection that occurred in the mid-1990s. This chapter also addresses the involvement of 
experts and the public in the drafting of the Opinion and its impact on further policy 
development. 
2.1 Developing an Opinion 
2.1.1 Reorganization to Regain Public Confidence 
In order to understand the work of the SCMPMD it is helpful to look into the context of its 
establishment. In 1997 the European Commission faced the severe political crisis of the BSE 
(Bovine Spongiform Encephalopathy, mad cow disease) scandal and an associated loss of 
public confidence in EU regulation. An interviewee explained that, amongst other measures, 
the Commission responded to this crisis by carrying out a “big reorganization of the scientific 
basis of the Community legislation" (a: 42-43). The European Commission created eight 
Scientific Committees,4 which would provide scientific advice “at the Commission’s request 
(…) on matters relating to consumer health and food safety” (EC 1997: Article 2.3.). By 
setting up the new advisory bodies and strengthening their scientific basis – previous 
advisory bodies were mostly composed so as to represent Member States - the Commission 
aimed at reaching two objectives: to regain public trust and to provide the basis for “good 
legislation" (a: 38 - 41). In order to achieve these goals the Commission formulated three 
central guiding principles on which its new Scientific Committees should be based on, i.e. 
“excellence, independence and transparency” (EC 1997). 
2.1.2 Scientific Committee without Regulatory Competencies 
Most of the newly established Scientific Committees replaced existing Committees (EC 
1997: Article 12). However, the SCMPMD was the only completely new one. Its task was to 
provide advice to the Commission on “scientific and technical questions relating to 
                                                     
2 in the late 1990s DG XXIV, in the following for reasons of simplicity DG SANCO. 
3 For a short overview see Tallacchini 2002: 371 ff.; for a critique Tallacchini 2011. 
4 This structure of the Scientific Committees was reorganized in 2004 and their number was reduced to three (see 
chapter 5). 
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Community legislation concerning medicaments for human and veterinary use” (ibid.). In 
addition, it had to deal with “scientific and technical questions relating to Community 
legislation concerning medical materials and equipment” (ibid.). However, as an interviewee 
stated, the SCMPMD was a "more difficult Committee” (a: 184-185). In contrast to other 
scientific committees, it lacked the responsibility to give authoritative advice on regulatory 
matters because this competence was, and still is, the domain of the EMEA/EMA (see 
chapter 4.2.3). In addition, the creation of the SCMPMD could potentially lead to a conflict 
between European Institutions, since the EMEA/EMA was, and still is, under the control of 
EU Member States, whereas the SCMPMD advised the European Commission (a: 197-207). 
In order to avoid conflicts between the EMEA and the SCMPMD as well as Member States 
and the European Commission, the Decision which set up the Scientific Committees states 
that the SCMPMD should do its work “without prejudice to the specific competences given to 
the Committee for Proprietary Medicinal Products and the Committee on Veterinary 
Medicinal Products in the evaluation of medicaments” (EC 1997: Article 12). This lack of a 
mandate in the regulation of medicinal products and devices made it difficult to find topics for 
the SCMPMD’s agenda. It was therefore more of a "prospective" than a regulatory 
committee (a: 198-199), “interested in future issues” (a: 258-262). Xenotransplantation, as 
will be described in this paper, was regarded as such a prospective issue. 
2.1.3 Recruitment and Composition 
Scientific Committees have a maximum of 19 members (EC 1997: Article 3.1), which are 
appointed by the Commission for a three years’ term (ibid. Article 5). The members are 
selected following an open call for expressions of interests. This call also includes the criteria 
by which Committee members are selected. The selection procedures have to be 
transparent and are intended to result in the “most suitable applicants for appointment to the 
Committees”. The Commission appoints members of Scientific Committees from a list of 
candidates, which is the outcome of this selection process. Their names are published (EC 
1997: Article 3.3). Committee members have to be “independent of all outside influence” 
(ibid. Article 6) and must declare any conflicts of interest. As an interviewee recalled, the 
goal of this procedure is to get "the best independent (...) scientists" (a: 92 ff.), who should 
impartially represent only themselves rather than being instructed by Member States (c.f. a: 
97-99, ibid. 162-163). Committee members mainly come from European universities and 
national research institutes but also from abroad. It is also possible that they are recruited 
from Ministries and in "exceptional cases (from) enterprises" (a: 92). 
2.1.4 Working Procedure 
Different Directorate Generals (DG) can request opinions from Scientific Committees. In 
working out opinions, the SCMPMD established working parties, which involved 
approximately five experts; some of these were members of the Scientific Committee, others 
were external experts. 
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The Scientific Committee appointed some of its members for the new working party. From 
this group a chairman was then appointed. The working party members next decided on key 
topics to be dealt with and identified external experts to cover the necessary competencies. 
External experts were identified from the committee members' own "scientific network": from 
a DG SANCO pool of external experts and from a literature review of experts (b: 110-114). 
The working party drafted its opinion throughout the course of several meetings, the 
progress of which was reported to the SCMPMD in plenary meetings . The Scientific 
Committee discussed the drafts (a: 311-315) and adopted a final version by holding a formal 
vote. 
Despite the Scientific Committee’s considerable autonomy, the European Commission 
played an important role in the SCMPMD. Firstly, several DGs were entitled to take initiative 
and ask for expert advice. Secondly, as the Commission Decision which established the 
Scientific Committees stipulated, the “Commission shall provide the secretariat of the 
Scientific Committees, the sub-committees and the working parties” (EC 1997: Article 9.2). 
Commission staff supports Scientific Committees in their work, e.g., by setting up agendas, 
inviting people, and writing minutes. DG SANCO staff also facilitated Working Group 
meetings (b: 117) by overseeing these tasks. Commission staff also adopted and approved 
agendas. Thirdly, in order to be useful to the Commission, the activities of Scientific 
Committee’s had to be linked to its needs for advice by addressing topics which were 
relevant to the Commission. In summary, an interviewee described the European 
Commission’s role as a management task, which involved the establishment of the 
Committees as such, the recruitment of "the best people, to make it work” and to ensure 
“that there is a relation between what they do and what the Institution wants" (a: 301-304). 
2.1.5 Public 
One of the aims for reorganizing scientific advice to the European Commission was the need 
to increase its transparency to the public. The Commission Decision, which established the 
new Scientific Committees, therefore stated, that “the agendas, minutes and opinions of the 
Scientific Committees shall be published without undue delay and with regard being had to 
the need of commercial confidentiality. Minority opinions shall always be included and shall 
be attributed to members only at their request” (EC 1997: Article 10). The fact that, minutes 
of plenary sessions, opinions and a report about their policy impact were published on the 
Internet, certainly contributed to this aim. However, the transparency aimed for was 
considerably curtailed by the fact that the minutes published were very brief and comprised 
of only a participant list, an agenda and a short summary of discussion results. They did not 
provide much detail about the actual content of discussion, let alone different opinions 
expressed. More importantly, draft papers and minutes of working parties, where the main 
work was done, were not put on the Internet at that time. The one page report about the 
Opinion’s policy impact is rather sparing of words (European Commission 2003: 24). 
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The next section leaves the general make up of the SCMPMD aside and focuses on the 
particular development of the Opinion on Xenotransplantation. 
2.1.6 Development of the Opinion 
The working party on xenotransplantation within the SCMPMD formulated its Opinion over a 
process of roughly two years, during which the issue was on the agenda in nine plenary 
meetings. The group met about ten times in Brussels to discuss the topic (b: 128). 
In February 1999 at its 8th meeting, the SCMPMD Chairman, Dr. Jones, mentioned five 
subjects that might in the future appear on the Committee’s list of items and asked the 
members to reflect on these issues. Xenotransplantation, among genetic therapy, live 
vaccines, tissue engineering as well as amalgam and other alloys for dentistry, was one of 
these issues listed in the minutes (SCMPMD 1999a). 
Responding to the question of why xenotransplantation became a topic for the SCMPMD, an 
interviewee explained that Scientific Committees had "some room of competence" and were 
able to suggest topics that they wanted to look into (a: 63-65); for this purpose, committee 
members carried out, what another respondent called, "risk watch". They were "aware of the 
developments in (their) specific area, and then if new things pop up in that area, which might 
have an effect on public health, it will be brought to the attention of the Scientific Committee" 
(b: 57-59). This was also the case with xenotransplantation. The topic "was put onto the 
agenda (…) because scientists (…) wanted to put (it) onto the agenda" (a: 218-219). As 
another interviewee confirmed, xenotransplantation was "more or less self tasking from the 
Scientific Committee" (b: 85). It was on a list of "emerging issues" set up by the Committee 
itself, which might "become a risk for the health of the population" (b: 31-33) and was 
regarded as an issue of "relatively high risk" (b: 79). The immediate trigger was the release 
of a number of publications that dealt with clinical trials and the "continuous need for organ 
donors" (b: 71-74). 
However, an issue had to pass several phases within the Committee in order to become 
topical. It first had to be raised, the Committee then had to agree and, finally, it had “to be 
brought to the attention of the Commission; they (had) to think about it" (b: 83-87). 
At the 11th meeting in September 1999, two meetings after the issue was raised for the first 
time in the SCMPMD, a representative of the Council of Europe (CoE) Health Division was 
invited and informed about relevant discussions within the CoE by the Scientific Committee. 
He explained the aim and organisation of the CoE, , the organisational bodies involved in 
this topic,5 as well as the principles6 and legal tools7 applicable in the case of 
                                                     
5 Committee of Ministers, European Health Committee (CDSP), Steering Committee on Bioethics (CDBI), Working 
Party on Xenotransplantation (SCMPMD 1999b: 4ff.) 
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xenotransplantation. Following the presentation, the SCMPMD Chairman requested that a 
working party be established to identify the interesting scientific points on the subject. This 
working party involved six Committee members.8 Some SCMPD members asked that 
external experts be integrated into the working party because its current members were not 
specialized in xenotransplantation. The working party was therefore  asked to identify 
external experts and invite them to future meetings. The EMEA representative present was 
also invited to contribute to the work and it was agreed that the EMEA would send a 
document on this subject to the working party (SCMPMD 1999b). 
At the 12th meeting, in December 1999, xenotransplantation was once again a topic for 
discussion. The working party reported on its current work and its chairman recognized that 
xenotransplantation had been the topic of debate at several international forums. The 
working party reported that it had discussed the issue and had agreed on a position paper, 
which would become a starting point for a more detailed document, which would be 
discussed by experts on xenotransplantation during a seminar that the working party had 
planned. Dr. Jones also stated that the work would be difficult and that a final draft was 
envisaged in twelve or more months (SCMPMD 1999c). 
In February 2000, at the 13th meeting, Dr. Jones reported that an internal preliminarily report 
for the use of the working party was being prepared. The SCMPMD also decided that it 
should also draw the European Commission’s attention to this subject. Because he was 
“unable to continue to chair the group” Dr. Jones suggested Dr. de Jong as a successor and 
asked to include yet another researcher, a veterinarian, into the working party (SCMPMD 
2000a). 
At the 14th meeting of the SCMPMD, in June 2000, the new Chairman, Dr. de Jong, informed 
the Committee about CoE documents on xenotransplantation and about his asking the 
Chairman of the CoE working group for cooperation (SCMPMD 2000b). The already 
established links between the SCMPMD and the CoE were thereby reinforced. 
                                                                                                                                                      
6 “non-commercialization of substances of human origin; ensure the dignity of the human being; maintenance and 
further realization of human rights and fundamental freedoms; protection of donors and recipients” (SCMPMD 
1999b: 4). 
7 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of 
Biology and Medicine. No. 164 on Human Rights and Biomedicine (1997). Protocol to the Convention on human 
rights and biomedicine on the prohibition of cloning human beings. Protocol to the Convention on human rights and 
biomedicine on organ transplantation (in consult period), Recommendation No (97) on Xenotransplantation. State of 
the Art report on Xenotransplantation. 
8 Dr. Jones (chairman of the working party); Prof. Williams (Senior Pro-Vice-Chancellor, Dept. of Clinical 
Engineering, The Royal Liverpool University Hospital, Liverpool, UK), Dr. de Jong (Senior scientific staff member, 
National Institute of Public Health and Environment, Bilthoven, Netherlands), Dr. Silbermann, Prof. Loewer (Acting 
Director, Paul-Ehrlich-Institut, Langen, Germany), Prof. Descotes. 
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In December 2000, at the 15th SCMPMD meeting, the working group reported its plan to 
finalize the draft opinion by mid 2001. Also, several new members were incorporated 
(SCMPMD 2000c).9 
At the 16th meeting, in February 2001, Committee members asked the working group to 
include several topics into the report, i.e. immunology, health of animals used in transplants, 
ethics, and stem cells. It was decided that the report should be discussed at the next 
meeting in May (SCMPMD 2001a). 
In May 2001, at the 17th SCMPMD meeting, a draft report was circulated within the Scientific 
Committee; however, it was stated that another working group meeting would be necessary 
to revise and finalize the document before the next plenary SCMPMD meeting (European 
Commission 2001a). 
The SCMPMD adopted the working groups’ report “Opinion on the State of the Art 
Concerning Xenotransplantation” on 1st October 2001. The minutes report that, “a productive 
discussion on the subject took place and the members of the Committee proposed several 
modifications to the report and to the Opinion” (European Commission 2001b). However, the 
records do not provide any details of what points were discussed, what modifications were 
considered necessary and in what way the paper was consequently changed. 
2.2 Content 
2.2.1 Objective 
The purpose of the “Opinion on the State of the Art Concerning Xenotransplantation” was to 
“report to the European Commission (DG SANCO) the current developments and concerns 
in the field of xenotransplantation and to indentify issues that may require community-wide 
action” (European Commission 2001c: 2). It should be noted, however, that the report was, 
as previously mentioned, solely an advice to the Commission; it did not constitute a decision 
on policies (see chapter 2.1.2). As a brief DG SANCO report in 2003 emphasised, the 
questions addressed in the Opinion on Xenotransplantation arose “on an ad hoc basis” and 
were “not associated with any specific legislation” (European Commission 2003: 24). 
2.2.2 Framing 
The SCMPMD Opinion is framed in the context of organ shortage, the risks of 
xenotransplantation and how to contain them, as well as a number of downstream ethical 
                                                     
9 Prof. Vannier (Directeur, Laboratoire d'Études et de Recherches Avicole et Porcine, Agence Française de Sécurité 
Sanitaire des Aliments, Ploufragan, France), Dr. Dobbalaer (Acting Head of Biological Standardisation Section, 
Ministry of Public Health, Institute for Hygiene & Epidemiology, Brussel, Belgium), Prof. Williams, Dr. Thomson and 
Dr. Madsen (Chief Physician, Aarhus University Hospital, Department of Renal Medicine, Århus, Denmark) 
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considerations regarding clinical trials and animal welfare, relevant if xenotransplantation 
were to become a clinical reality. One interviewee described the Opinion as "focused on the 
public health risks" (b: 142-143), while ethical issues “were not extensively addressed. (…). 
The Working Group dealt more with scientific issues of xenotransplantation and potential 
risks, both for the patient or for the environment of the patient" (b: 317-319). As another 
respondent commented, the Committee focused on scientific questions and deliberately left 
ethical questions to politicians. The SCMPMD considered itself not as an ethics but as a 
scientific committee, which meant that politicians would have to take into account the ethical 
problems of xenotransplantation (a: 350-352). 
2.2.3 Potentials, Risks and Costs 
The Opinion frames xenotransplantation as an international problem and takes into account 
reports of international organisations such as the Council of Europe (CoE 2000), the OECD 
(1999), and the World Health Organization (WHO 1998; European Commission 2001c: 5, 7, 
8, 10).10 
The Opinion reports that the CoE Parliamentary Assembly unanimously adopted a 
recommendation to ban xenotransplantation, which called for a “legally binding moratorium 
on all xenotransplantation in humans, including clinical trials” (ibid. 4). The Opinion, however, 
states that no European wide legislation had so far implemented this CoE recommendation. 
The paper neither takes an explicit position against or in favour of a moratorium nor 
discusses the topic any further. However, it criticizes the fact that there were no information-
sharing procedures in place between countries. It demands international cooperation and 
claims that it is necessary to “re-examine the strategies in place and options available to 
support and control xenotransplantation as well as to ensure public health” (ibid. 4). 
Xenotransplantation, defined as transplantation of animal cells, tissues or organs into 
humans, is described as a promising solution to organ shortage and a possible alternative to 
the use of human or artificial materials.11 Nevertheless, it is not presented as a panacea to 
organ shortage. On the contrary, it claims that the public should continue organ donation 
(ibid. 13) and that stem cell technology may be a viable alternative (ibid. 14). While organ 
shortage is presented as a main motive for exploring xenotransplantation, the paper does 
not focus on whole organ xenotransplantation. In fact, this option is dismissed as being at a 
                                                     
10 This indicates an international network of scientists, experts and policy makers which already became apparent in 
the case of OECD xenotransplantation policies (Griessler 2012). Also Tallacchini (2011) emphasizes the cooperation 
between CoE and the SCMPMD. Commission staff participated, for instance, in the CoE Working Party on 
Xenotransplantation (Council of Europe 2003: 7) and at an international meeting organized by the OECD (Griessler 
2012). Unfortunately, requests for interviews about these activities of Commission staff in xenotransplantation 
policies were denied. 
11 Xenotransplantation is defined as “any procedure that involves the transplantation or infusion into a human 
recipient of (a) living cells, tissues, or organs from a non-human animal source, or (b) human body fluids, cells, 
issues or organs that have ex vivo contact with living non-human animal cells, tissues or organs (e.g. extracorporal 
perfusion)” (European Commission 2001c: 5). 
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premature stage, while xenotransplantation of cells and extracorporeal liver perfusion, where 
clinical trials were already being carried out, is regarded as the more relevant development 
in xenotransplantation (ibid. 5). 
The Opinion discusses the advantages and disadvantages of using non-human primates as 
source animals and concludes that, “pigs were the most likely species to be used in 
xenotransplantation” (ibid. 6). 
The document identifies the possible spread of infectious diseases as the greatest problem 
of xenotransplantation. The significant risk that an immunosuppressed host would be 
infected by pathogens from transplanted animal cells would not only pose a threat to the 
individual patient but also to the wider public (ibid. 7). Furthermore, new diseases might arise 
in this manner and present new and unforeseeable health care problems of their own. 
The paper discusses the management of the inherent infection risk of xenotransplantation by 
“breeding of pigs in a barriered environment” with regular screening for infections (ibid. 8). 
However, this would not help to prevent the spread of unknown viruses and PERV (porcine 
endogenous retroviruses), which would “pose the most obvious risk at present” (ibid. 8 ff.). 
Surveillance is discussed as the necessary procedure for managing what is regarded as a 
global infection threat posed by xenotransplantation. From this perspective, the report calls 
for international cooperation and suggests that an international agency such as the WHO 
should function as a central distributor of information. Registration, surveillance and 
monitoring would apply to xenotransplantation recipients as well as others at risk (such as 
carers, close relatives, visiting friends, neighbours and others) but would also extend to the 
source animals and their husbandry staff (ibid. 10). 
Xenotransplantation is also perceived as a means to lowering costs in the health care 
system; savings may result from not having to pay for chronic treatments and by people 
being able to return to work (ibid. 13). 
2.2.4 Ethical issues 
Although the Opinion recognizes the importance of “ethical, social, and religious values and 
perceptions”, which might also influence the public’s perception of xenotransplantation, it 
does not “consider” them “in detail” (ibid. 4). Instead, it “addresses and identifies the 
scientific issues that are considered important areas on which the European Commission 
should focus” (ibid. 4). The document takes it for granted that xenotransplantation is ethically 
acceptable. The document intends recommendations made therein to be applied to the 
routine use of xenotransplantation if and when this is introduced. In other words, given that 
xenotransplantation were to become a routine practice, these would be the 
recommendations to be followed. 
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Ethical considerations, which are made, nevertheless arise for humans under strict 
surveillance conditions, which would be necessary for xenotransplantation (ibid. 10). Among 
the issues raised are: whom to control, for how long and whether to restrict freedom of travel. 
It is mentioned that some of the surveillance measures may be in violation of the Declaration 
of Helsinki and other guidelines for research on human subjects (“right of a subject to 
withdraw from a clinical trial”, ibid. 11). Patients  could therefore “have to agree to waive 
some of their human rights” (ibid.). Mariachiara Tallacchini sharply criticizes this position 
because it favors the prevention of collective risks over the human rights of an individual 
(2011: 177ff). 
As already mentioned, the Opinion recognizes that “xenotransplantation raises ethical as 
well as scientific considerations for all those involved” (European Commission 2001c: 11). 
However, it does not “focus” on these questions “in detail”, but instead lists a number of 
practical questions on such matters as “obtaining informed consent from the early clinical 
trial patients, the gaining of consent from non-transplanted persons in contact with the 
patient for surveillance purposes (including animal handling staff, nursing staff and those 
dealing with patient samples), archiving of samples, data protection of personal details, 
dissemination of results, confidentiality by contributing commercial companies, and even 
perhaps, how to handle breaches of agreed contract when others may be put at risk” (ibid. 
11 ff.). 
Members of the working party unanimously take it for granted that it is ethically permissible 
to kill animals in cases where there is a human health benefit. However, it is also conceded 
that different groups of animal welfare activists might disagree. Some of them would object 
to the right to kill animals altogether; others would “wish to be reassured that animals are 
being kept in the best possible conditions under the circumstances” (ibid. 12). It is also 
recognized that the breeding of transgenic animals is subject to public controversy. The 
report only mentions these positions without discussing them. The report deals with animal 
welfare issues briefly but nevertheless raises a number of practical ethical concerns and 
formulates several measures to address them. For example, it is mentioned that the health 
of source animals, i.e., should be monitored by people “trained in animal welfare assessment 
and the results recorded and published” (ibid.). The animal welfare problem of keeping 
source animals isolated in specific pathogen free or designated pathogen status is raised; 
due to “serious ethical concerns” it is suggested that pigs not be kept in isolators but instead 
in barriered groups so that they are “able to interact with other animals” (ibid. 12 ff.). This 
focus on practical measures might be attributable to the fact that several working party 
members were veterinarians by training (b: 100). However, the ethical question of trans-
species transplantation, or mixing humans and non-human animals, is not discussed in the 
paper. 
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2.2.5 Public 
The document does not raise the issue of public participation in the development of EU 
xenotransplantation policies. However, it raises the issue of public trust and calls for caution 
when it refers to Acquired Immune Deficiency Syndrome (AIDS) and BSE as examples of a 
”public health crisis”. The Commission should be aware of “public sensitivity” in this area and 
take measures “to give the public confidence that the risks of xenotransplantation will be 
thoroughly examined” (ibid. 9). 
2.2.6 Recommendations 
The document includes the following recommendations (14 ff.): 
I. The European Commission should propose the establishment of a centralised 
regulatory body to oversee the process and to minimise the risks; 
II. the European Commission should carry out a thorough and ongoing risk analysis of 
xenotransplantation on the basis of the results of both research and clinical trials; 
III. specific measures for clinical trials dealing with authorisation, informed consent, 
registration, surveillance of patients and those at risk should be defined on the basis 
of Directive 2001/20/EC of the European Parliament and of the Council “on the 
approximation of the laws, regulations and administrative provisions of the Member 
States relating to the implementation of good clinical practice in the conduct of 
clinical trials on medicinal products for human use” (ibid. 14); 
IV. appropriate quality requirements related to health status, animal welfare and animal 
production should be defined and implemented for xenotransplantation source 
animals; 
V. appropriate quality requirements for procurement of organs and their clinical use 
should be formulated and implemented for centres performing xenotransplantation; 
VI. requirements for surveillance should be defined and implemented for source 
animals, xenotransplantation recipients and others at risk; 
VII. the European Commission should stimulate and support research on detecting and 
understanding the risks of viral infections with respect to xenotransplantation; 
VIII. and it should stimulate research on detecting and understanding the risks associated 
with severe immunosuppressive drug therapy, especially relating to interference with 
other drug therapy. 
2.3 Policy impact 
The policy impact of the Opinion is hard to substantiate for several reasons. First, as already 
mentioned, the initiative to deal with xenotransplantation came from the SCMPMD and was 
“not associated with any specific legislation” (European Commission 2003: 24). A DG 
SANCO report states that, “the opinions contributed to drafting of the Commission proposal 
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for an European Parliament (EP) and Council Directive setting standards of quality and 
safety for the donation, procurement, testing, processing, storage and distribution of human 
tissues and cells” (European Commission 2003: 24). However, the report does not state 
what these contributions were exactly. No references were made to the Opinion in available 
documents dealing with Directive 2001/20/EC on clinical trials. One respondent was 
altogether unsure what happened with the Opinion (b: 263). 
2.4 Public Involvement 
The main motive to create the new Scientific Committees was to regain public trust, which 
was severely jeopardized by the genetically modified organism (GMO) and BSE crises. The 
reorganisation therefore emphasised three principles, i.e., excellence, independence and 
transparency. 
Excellence was strengthened by the objective to recruit the best scientists as well as by the 
central aim of the new Scientific Committees to conduct sound science without being 
influenced by Member States’ politics. Independence was strengthened by the fact that 
members were no longer nominated by the Member States and had to express potential 
conflicts of interest. Transparency was strengthened by recruitment after open calls for 
expressions of interest as well as the publication of (a) selection criteria, (b) Committee 
members, (c) statements about potential conflicts of interest, (d) minutes, and (e) opinions. 
However, although transparency was a precondition, this is not the same as public 
involvement. It is therefore necessary to address the question how experts and the public 
were involved in practices that constituted the work of the SCMPMD and which entry points 
for the public existed therein. 
A number of routine practices can be identified in the working of the SCMPMD. These are, 
e.g., recruiting members, putting topics on the agenda, framing topics, recruiting working 
party members and external advisors, cooperating with international organisations, 
organising meetings, working in plenary meetings and working parties, drafting papers. 
• As has already pointed out, members were not nominated by Member States but 
selected according to defined criteria after applicants expressed their interest in an 
open call. The public was informed about this process. 
• The recruitment of working parties can be described as a self-selecting process of 
experts controlled by the SCMPMD and the Commission. Working party members 
were expert scientists selected from the SCMPMD members’ networks, a DG 
SANCO pool of experts or were on the basis of a literature review. 
• Topics were put on the agenda either by different DGs within the European 
Commission or by the SCMPMD. They either arose from the European 
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Commission’s own needs for advice or  what SCMPMD experts considered relevant 
developments in health. The public was not involved in this selection process. 
• Xenotransplantation was framed by the SCMPMD; it was framed rather narrowly by 
sound science, i.e. questions which can be addressed by scientific methods. As an 
interviewee recalled, the SCMPMD‘s task was to "weigh the evidence" and to come 
to "a decision or conclusion" (b: 270). For the most part, ethical questions were 
considered to be outside of the scope of the Scientific Committee; they were 
restricted to animal welfare and only dealt with rather briefly. The public had no 
influence on how the topic was framed. 
• The working party collaborated with international organisations such as the OECD. 
This cooperation is important because it contributed to establishing and sustaining 
an international network of high-level experts and policy makers (epistemic 
community) with shared beliefs and assumptions about xenotransplantation and its 
regulation (Griessler 2012). 
• Plenary Meetings and even more so meetings of working parties were important 
occasions, where papers were drafted, discussed and rewritten. However, these 
documents were not open to the public. Opinions and minutes about plenary 
meetings were published though but, as has already been said, provided little 
information in terms of content. Moreover, there were no minutes of working party 
meetings, where most of the work was done. 
The public had almost no entry points to most of the aforementioned routine practices. It was 
mainly defined by the SCMPMD as an outsider who should be notified about its activities 
with well-measured information.  
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3 Promising Economic Area 
At the European Council in Lisbon, in March 2000, the goal to become the leading 
knowledge-based economy was set. The Commission therefore decided to agree on a 
strategy for life sciences and biotechnology for the next years.12 The following year the 
Commission published the consultation document “Towards a strategic vision of life sciences 
and biotechnology” (EC 2001) and called for comments by interested groups and the general 
public. Xenotransplantation was identified as one new research area, which would potentially 
require further investigation. During the consultation process a stakeholder conference took 
place from September 27th to 28th 2001. Representatives from several DGs (Research, 
Health and Consumer, Enterprise and Innovation) and the Deputy Secretary General were 
involved. After the consultation phase, the Commission published “Life sciences and 
biotechnology — A strategy for Europe”,13 which consisted of policies and points of action. 
Xenotransplantation was described as offering the “prospect of replacement tissues and 
organs to treat degenerative diseases and injury resulting from strokes, Alzheimer’s and 
Parkinson’s diseases, burns and spinal-cord injuries” (EC 2002:11). It was also identified as 
an area where ethical considerations required further attention. The Commission monitored 
the implementation of its strategy and published several progress reports in 2003, 2004, and 
2005, which do not refer to xenotransplantation again. Economic framing disappeared after 
xenotransplantation did not fulfill the Commission’s high hopes.  
                                                     
12 For details and reports see: http://ec.europa.eu/biotechnology/index_en.htm (accessed:1/2/12) 
13 Communication from the Commission to the European Parliament, the Council, the Economic and Social 
Committee and the Committee of the Regions (COM(2002) 27), http://ec.europa.eu/biotechnology/pdf/com2002-
27_en.pdf (accessed: 1/2/12) 
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4 Regulating Xenotransplantation 
4.1 Clinical Trials 
In September 1997 the European Commission sent out a proposal for a Directive regulating 
clinical trials14 (Commission of the European Communities 1997), which was finally accepted 
more than three years later; this occurred in April 2001 after a codecision process, several 
amendments and compromises between the European Institutions. As Commissioner 
Liikanen stated in 2000 in a speech to the European Parliament, the aim of the Directive was 
to harmonize European legislation in order to avoid “difficulties both for participants in clinical 
trials and industrialists who want to conduct such trials in the European Union” (European 
Parliament 2000). The Directive lays down under what conditions clinical trials have to be 
carried out in Europe and how they are to be transformed into national law by EU Member 
States (Cozzi et al. 2009: 208 ff.). 
4.1.1 Content 
In general the Directive makes clinical trials subject to authorization by a national ethics 
committee and a regulatory authority (Directive 2001/20/EC: Article 2 (k), Article 6, and 
Article 9). In other words, approval is mandatory for each clinical trial. An authorization by a 
competent authority must be completed within 60 days, a period that can be extended by 30 
days or more in the case of gene therapy products. The Directive explicitly addresses  the 
use of xenogeneic cell therapy because it states that in the case of xenogeneic cell therapy 
“there shall be no time limit to the authorisation period” (ibid. Article 6.7). Furthermore, 
“written authorisation shall be required before commencing clinical trials involving medicinal 
products for gene therapy, somatic cell therapy including xenogeneic cell therapy” (ibid. 
Article 9.6). Ethics committees and regulatory authorities are therefore not obliged to answer 
a request for a clinical trial in xenotransplantation within a certain period of time and trials 
cannot start until an opinion is provided. An interviewee interpreted this as a “sort of tacit, 
implicit moratorium or at least enabling a tacit moratorium by the Member States, because 
simply you can just postpone the delivery of your opinion”. It is, in her opinion, “a very (…) 
under the surface proceeding, so keeping xeno alive and at the same time being compliant 
with Member States’ will” (c: 231-245). The following section will address the question of how 
this clause came about and who was involved in its formulation. 
                                                     
14 The Directive defines clinical trials as: “any investigation in human subjects intended to discover or verify the 
clinical, pharmacological and/or other pharmacodynamic effects of one or more investigational medicinal product(s), 
and /or to identify any adverse reactions to one or more investigational medicinal product(s) and/or to study 
absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object 
of ascertaining its (their) safety and/or efficacy” (Directive 2001/20/EC, Article 2 (a)). As “good clinical practice” the 
directive defines “a set of internationally recognised ethical and scientific quality requirements which must be 
observed for designing, conducting, recording and reporting clinical trials that involve the participation of human 
subjects. Compliance with this good practice provides assurance that the rights, safety and well-being of trial 
subjects are protected, and that the results of the clinical trials are credible” (Directive 2001/20/EC: Article 1, 2). 
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4.1.2 Procedure 
Drawing on documents accessible at PreLex,15 it becomes apparent that the law making 
procedure started with a proposal for a Directive (97/0197 (COD)) presented on 3 
September 1997 by the Commission to the Council and the European Parliament for a 
codecision to be made (Commission of the European Communities 1997). The draft 
Directive was prepared by the Commission under the responsibility of DG03 and the 
involvement of six other Directorates. This draft, however, did not yet include any special 
clauses for xenotransplantation. 
On 19 September 1997 the proposal was referred, within the European Parliament, to the 
Committee on Environment, Public Health and Consumer Protection as well as the 
Committee on Budget for its opinion. On 1 October 1997 it was also sent to the Committee 
on Research, Technological Development and Energy.16 The Committee on Environment, 
Public Health, and Consumer Protection discussed the proposal twice in autumn 1997. 
Several amendments were suggested; one of which mentioned xenotransplantation: 
Article 4 (4) dealt with an additional time limit for ethics committees to receive supplementary 
information from an applicant. Amendment 12 of Article 4 (4) of the Commission draft limited 
this time span to 15 days and stated that “no additional extension shall be permissible 
beyond that limit, except in the case of trials involving gene therapy and xenotransplantation” 
(European Parliament 1998a). The explanatory statement does not mention why this 
exception for xenotransplantation was made. The draft legislative resolution was adopted 
unanimously. 
After its first reading on 16 November 1998, the European Parliament approved of the 
Commission proposal with amendments on the following day (Official Journal of the 
European Communities 1998: C 379/17). Amendment 12 regarding xenotransplantation was 
also adopted. 
On 26 April 1999 the Commission adopted an amended proposal and sent it to the Council 
and the European Parliament on 27 April 1999. It did not take into account Amendment 12 of 
Article 4 (4), as requested by the European Parliament, thereby providing an exception for 
xenotransplantation and extending the deadline for provision of additional information to the 
ethics committee (Official Journal of the European Communities 1999: C 161/13). 
                                                     
15 http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=de&DosId=21434, accessed 30/12/11 
16 The Committee on Research, Technological Development and Energy (Draftman Umberto Scapagnini) met three 
times from February to June 1998 but did not make any changes involving xenotransplantation (European 
Parliament 1998a). 
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On 25 May 2000 the Ministers’ Council reached political agreement on the Directive by a 
qualified majority, where the Austrian delegation voted against it (Counseil/00/180).17 The 
proposal was an item “B” on the Council agenda. The topic of xenotransplantation was not 
mentioned in the minutes. It was decided to adopt the proposal as a common position as an 
“A” item. 
On 20 July 2000 the Ministers’ Council adopted a common position as item “A” on its agenda 
(Official Journal of the European Communities 2000). In Article 4, paragraph 7 it states that, 
“No extension to the time period referred to in paragraph 5 shall be permissible except in the 
case of trials involving medicinal products for gene therapy and somatic cell therapy 
including xenogeneic cell therapy” (ibid.). Ethics committees and national authorities would 
therefore have unlimited time to produce an opinion in these cases. Article 7 
“commencement of clinical trial”  in paragraph 6 reads: “Written authorisation shall be 
required before commencing clinical trials involving medicinal products for gene therapy, 
somatic cell therapy including xenogeneic cell therapy and all medicinal products containing 
genetically modified organisms” (ibid.). The common position is thus stricter in these cases 
than in other clinical trials. No clinical trials can be started without written consent, which is 
not bound by a time limit. The statement of reasons explains that, “The second part of 
amendment 12 (Article 4 (7)), concerning an exceptional extension of the 60-day period for 
the Ethics committee to give its opinion in cases where trials involve medicinal products for 
gene therapy was accepted by the Council and extended to include somatic cell therapy, 
including xenogeneic cell therapy” (Council of the European Union 2000: 4). 
With the Rapporteur, Peter Liese, the Committee on the Environment, Public Health and 
Consumer Policy of the European Parliament adopted a Recommendation for Second 
Reading on 21 November 2000 (European Parliament 2000a). This document did not 
mention any amendments with regards to xenotransplantation. Xenotransplantation was also 
not mentioned in the parliamentary debate on 12 December 2000 (European Parliament 
2000b). 
On 14 December 2000 the European Council adopted a position towards the Second 
Reading of the European Parliament. It “approved by a qualified majority, with the 
Netherlands delegation voting against, all the amendments to the common position adopted 
by the European Parliament” (Council of the European Union 2001a: 6).18 In another Council 
Meeting on 26 February 2001 a qualified majority was again in favour of the proposal, 
against the vote of the Netherlands. 
As a result of this process at the European level there is no formal moratorium in place on 
clinical trials with xenotransplantation. In principle clinical trials in xenotransplantation are 
                                                     
17 No explanations are given, why Austria voted in this way. 
18 No reason was given why the Netherlands voted in this way. 
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possible but they are subject to a regulation, which enables national authorities to postpone 
them for an unlimited time span. The documents accessible at PreLex show that this 
regulation stemmed from the European Council. However, the available documents do not 
provide any reasoning for why this decision was made. None of the documents provide 
information as to why this amendment was made and clinical trials in xenotransplantation are 
more restrictively regulated than in other areas. 
The development of the Directive followed the process of codecision, which in a highly 
complex choreography involves different players in the European Commission, the European 
Council and the European Parliament (Pernicka/Biegelbauer 2002, Peterson/Bomberg 2000, 
Wallace 2005). This process remained highly opaque to outsiders and the public because 
there was only little information available to explain why certain decisions were made and 
where the impetus to make them came from. Interested citizens can get information by 
visiting the official PreLex website and downloading the published documents but these 
sources do not provide an answer to the question of why these particular policies were 
made. They lack any explanatory information about this issue. This state of opaqueness is 
aggravated by the fact that it turned out to be impossible to get more information about the 
law making process because an interview with the responsible Rapporteur was denied. It 
remains unclear whether the SCMPMD Opinion was taken into consideration at all, and 
which experts and stakeholders were involved as advisors on what issues. The complexity 
and insulation of this law making process and the scarceness of information available is one 
important factor hampering citizen participation in European Institutions. 
4.2 Medicinal Products 
At the EU level several legally binding provisions for xenotransplantation exist. These include 
Directive 2001/83 EC on the Community code relating to medicinal products for human use 
(amended by Directive 2008/29/EC), the already discussed Directive 2001/20/EC on clinical 
trials and Regulation (EC) No. 726/2004 that lays down Community procedures of the 
supervision of medicinal products for human and veterinary use and establishes a European 
Medicines Agency (Straßburger 2008: 299).19 We will only briefly deal with these Directives 
and Regulations because the process of their development and involvement of the public do 
not differ to a great extent from the process already described. Instead we will look more 
thoroughly into the way in which the European Medicines Agency produced its guidelines. 
4.2.1 Directive 2001/83/EC 
In 2001 Directive 2001/83/EC, on the community code relating to medicinal products for 
human use, was established (Cozzi et al. 2009: 208). There were no specific provisions on 
                                                     
19 In 2001 Directive 2001/18/EC, on the deliberative release into the environment of genetically modified organisms, 
established legal provisions applicable to xenotransplantation although this was not directly addressed (Cozzi et al. 
2009). 
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using xenogeneic cells. In 2003 this Directive was amended by Commission Directive 
2003/63/EC. Regulatory oversight on xenotransplantation, in the field of medicinal products, 
was thereby established since xenogeneic cell therapy was incorporated into the Annex I 
(Part IV) to the EU Directive on medicinal products. Part IV.4. A “specific statement on xeno-
transplantation medicinal products” states that, “detailed information related to the following 
items shall be provided according to specific guidelines: 
• Sourcing of the animals 
• Animal husbandry and care 
• Genetically modified animals (methods of creation, characterization of transgenic 
cells, nature of the inserted or excised (knock out) gene) 
• Measures to prevent and monitor infections in the source/donor animals 
• Testing for infectious agents 
• Facilities 
• Control of starting and raw materials 
• Traceability (Directive 2001/83/EC) 
4.2.2 Regulation (EC) No 1394/2007 
In December 2007 Regulation (EC) No 1394/2007 on advanced therapy medicinal products 
(ATMP) was approved and actually entered into force on 20 December 1998. ATMP include 
products relating to gene therapy, somatic cell therapy and tissue engineering (Cozzi et al. 
2009: 209).20 The main goal of the Regulation was to establish “a centralized authorization 
procedure for all AMTP through an interdisciplinary expert committee, the Committee for 
Advanced Therapies (CAT) within the European Medicines Agency (EMA), as the main 
accountable body in defining and evaluating advanced therapies” (Tallacchini/Beloucif 2009: 
184). This also included “specific provisions concerning the authorisation, supervision, and 
pharmacovigiliance of xenogeneic medicinal products” (Straßburger 2008: 299, 
Tallacchini/Beloucif 2009: 183). Once granted by the European Commission, a centralised 
marketing authorization is valid in all European Union and EEA-EFTA21 states. The main 
responsibility of the CAT is to prepare a draft opinion on each ATMP application submitted to 
the European Medicines Agency, before the EMEA’s Committee for Medicinal Products for 
Human Use (CHMP) adopts a final opinion on the granting, variation, suspension or 
revocation of a marketing authorisation for the particular medicinal product. 
During the inter-institutional negotiations over the ATMP regulation, ethical concerns 
generated political conflict. Some stakeholders raised objections to the use of human 
embryonic stem cells, or human-animal hybrids. The regulation therefore states that it does 
                                                     
20 Up to 2008 regulations for cell-based therapies and tissue-engineering products were developed separately from 
those concerning xenotransplants, but Regulation (EC) 1394/2007 meant that the European Union had one single 
regulatory provision covering all ATMP (human and animal). 
21 Iceland, Liechtenstein and Norway 
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not override member states’ individual decisions on the use of specific human (e.g. human 
embryonic stem cells) or animal cells (Farrell 2009: 55). 
4.2.3 Guidelines Developed by EMA 
The Commission set up various decentralized agencies to cope with the exceedingly 
demanding EU regulation. One of these, the European Medicine Agency (EMA) deals with 
the “evaluation and supervision of medicines for human and veterinary use“ in the EU 
(European Medicines Agency 2012, Garattini/Bertele 2004). Though EMA has no formal 
power to make decisions concerning the authorization of medicinal products, it is “de facto, if 
not de jure, a ‘quasi’-decision-making agency as the Commission normally decides upon its 
recommendations” (Borrás et al. 2007: 592, emphasis in the original). 
As already mentioned, Regulation (EC) 1394/2007 established a centralized market 
authorization procedure. Medicines that must be approved by the EMA through this 
procedure include: all medicines for human and animal use derived from biotechnology and 
other high-tech processes, all advanced-therapy medicines and human medicines intended 
for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune 
and other immune dysfunctions, and viral diseases, all designated orphan medicines 
intended for the treatment of rare diseases, as well as all veterinary medicines intended for 
use as performance enhancers. Other tasks of the EMA include monitoring the safety of 
medicines through a pharmacovigilance network, playing a role in stimulating innovation and 
research in the pharmaceutical sector and providing scientific advice and other assistance to 
companies for the development of new medicines. The EMA also publishes guidelines on 
quality, safety- and efficacy-testing requirements. 
4.2.3.1 Organization 
A 35-member management board, whose members should be independent from any 
government or organisation, sets the Agency’s budget, approves the annual work 
programme and is responsible for ensuring that the EMA works effectively and cooperates 
successfully with partner organisations across the EU and beyond. EMA staff is responsible 
for the administrative and procedural aspects of European Union regulations and directives 
related to the evaluation and safety-monitoring of medicines in the EU. The Agency’s six 
scientific committees22 are composed of independent professionals nominated by Member 
States from a pool of over 4,500 European experts. These committees are responsible for 
the scientific evaluation of marketing authorisation application dossiers submitted by 
pharmaceutical companies. They also provide opinions on referrals and other issues 
                                                     
22 These are: Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for 
Veterinary Use (CVMP), Committee for Orphan Medicinal Products (COMP), Committee on Herbal Medicinal 
Products (HMPC), Paediatric Committee (PDCO), Committee for Advanced Therapies (CAT) 
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impacting on public health, at the request of the Member States, the European Commission 
or the European Parliament. 
The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing 
the EMA's opinions on all questions concerning medicinal products for human use, including 
xenogeneic cell therapy medicinal products, based on a draft opinion for ATPM prepared by 
the Committee for Advanced Therapies (CAT). The CHMP also provides scientific and 
regulatory guidelines for the pharmaceutical industry, e.g. the “Guideline on Xenogeneic 
Cell-Based Medicinal Products” (European Medicines Agency 2009). 
CHMP members and alternates are nominated by the Member States, in consultation with 
the European Medicines Agency Management Board. They serve on the committee for a 
renewable period of three years.23 The CHMP has several working parties and scientific 
advisory committees. Within the CHMP there are also temporary working parties, drafting 
groups, scientific advisory groups and other CHMP-associated groups.24 
The CAT’s (Committee’s for Advanced Therapies) main responsibility is to assess the 
quality, safety and efficacy of ATMPs and to follow scientific developments in the field. It is a 
multidisciplinary committee, also including two representatives from patient organizations. 
4.2.3.2 Development 
Already in 2000 the Biotechnology Working Party in the Committee for Proprietary Medicinal 
Products (CPMP)25 suggested that a guidance document on xenogeneic cell therapy 
products be produced (EMEA 2000). The impetuses for such a document were perceived 
regulatory gaps and the fact that manufacturers were already “developing xenogeneic cell 
therapy products” (ibid. 1). The paper proposing such a document also pointed out that, “the 
use of xenogeneic cells or tissues involves serious ethical, scientific, public health and other 
issues” (ibid.). However, it also clarified that the planned guidance document did “not indicate 
an acceptance of clinical development of xenogeneic cell products, but rather, should serve 
as a tool for harmonising the approach to the evaluation of medicinal products containing 
xenogeneic cells” (ibid.). The aim of a guidance document was “to establish a common 
scientific view with the European Union on the special requirements concerning quality, 
                                                     
23 The CHMP is composed of: 
• a chairman, elected by serving CHMP members; 
• one member (and an alternate) nominated by each of the 27 EU Member States; 
• one member (and an alternate) nominated by each of the EEA-EFTA states, Iceland and Norway; 
• up to five co-opted members, chosen among experts nominated by Member States or the European 
Medicines Agency and recruited, when necessary, to gain additional expertise in a particular scientific 
area. 
24 The current CHMP standing working parties are: Biologicals Working Party, Patients' and Consumers' Working 
Party, Pharmacovigilance Working Party, Quality Working Party, Safety Working Party, Scientific Advice Working 
Party. 
25 The CPMP is the predecessor of the already mentioned CHMP. 
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safety, efficacy and surveillance of xenogeneic cell therapy medicinal products. It is a means 
for harmonization of the technical requirements” (j: 3). The planned guidance document was 
to cover the issues of “choice of animal species, animal husbandry, quality issues in the 
production process, requirements for preclinical testing, requirements for clinical evaluation, 
need for special clinical safety monitoring (…) public health issues” such as “follow up of 
individuals in close contact with the patient, archives for human tissue samples, need for 
special surveillance systems” (EMEA 2000: 2). The document proposed the creation of a 
multidisciplinary team, including veterinary experts, for the organization of expert meetings 
on the topic. 
Since the development of the guideline was a multidisciplinary task, the group responsible 
for drafting the document “included members (‘Rapporteurs’) from the Biotechnology 
Working Party, the Safety Working Party, the Efficacy Working Party and the 
Pharmacovigilance Working Party, together with veterinary experts in the field of animal 
husbandry, viral risk and zoonoses. EMA staff assisted this expert group“ (j: 2). 
In 2001 the ad hoc group on xenogeneic cell therapy met twice and prepared a “points to 
consider document on the quality and manufacturing aspects of cell therapy products” 
(EMEA 2002a: 20). A further meeting was held in February 2002, during which the experts 
“reviewed current scientific and regulatory approaches and experience in this field”. The 
meeting focused on “safety aspects, methods available to minimize viral risks, special 
methodological aspects to be considered for clinical efficacy, post exposure safety 
monitoring and surveillance” (CPMP 2002a: 20). In 2002 an expert workshop was held, 
which involved “experts in the field, members from the involved working parties, 
representatives from US-FDA26 and US-CDC27 representatives from the European 
Commission and the Council of Europe” (j: 2). In addition, a Rapporteur’s meeting was held 
in the same year, which should have “allow(ed) the Rapporteurs from the different working 
parties to gather the latest scientific information” and “to finalize the draft xeno guidance” (j: 
3). These two events “led to the preparation - in consultation with the reworking parties and 
the CVMP - to a Points to consider paper on xenogeneic cell therapy medicinal products” 
(EMEA 2002b: 23).28 The paper was released for a six months’ consultation period in 
November 2002 (CPMP 2002b: 23). 
The final 24-page version of the “Points to Consider on Xenogeneic Cell Therapy Medicinal 
Products” was published in December 2003 (EMEA 2003). Again, it explicitly stated that it 
would not discuss religious, ethical or legal implications of xenotransplantation, as this was 
not the Committee’s task (ibid. 3). It emphasized that the guidelines should not be 
interpreted as a promotion of clinical trials, including animal cells (ibid.). Rather, they were 
intended to provide some general principles that could be used if regulatory agencies within 
                                                     
26 Food and Drug Administration 
27 Center for Disease Control and Prevention 
28 CVMP = Committee for Medicinal Products for Veterinary Use. 
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the EU were to deal with a marketing authorization application. In the document, xenogeneic 
cell therapy29 is regarded as attractive due to the limited availability of human cells and the 
relatively reduced risk of immune rejection compared with solid organ xenograft (ibid. 16). It 
formulates a complex and wide ranging system of regulations including documentation, long 
term archiving and surveillance, which must be in place before products using xenogeneic 
cells were authorized to enter into preclinical and clinical testing. The document covers the 
following issues in detail: 
• Sourcing of animals 
• Manufacturing 
• Non-clinical testing 
• Human efficacy and safety  
• Pharmacovigilance and special surveillance methods 
In October 2009 the CHMP adopted the “Guideline on Xenogeneic Cell-Based Medicinal 
Products”. This much shorter 14-page document replaced and revised the 2003 “Points to 
Consider”. The purpose of these guidelines was to provide general principles for the 
development and assessment of xenogeneic cell-based products to ensure that these are of 
acceptable quality and standard as well as free of contamination. While intended for 
products entering the marketing authorization procedure, the document emphasises that 
guidelines should already be considered at the earlier stage of entering into clinical trials. 
The document focuses on scientific requirements but also identifies requirements for suitable 
animal husbandry, in terms of animal welfare, thereby also including ethical considerations 
(European Medicines Agency 2009). 
The Cell Products Working Party (CPWP), in cooperation with other relevant working parties, 
prepared the first draft of the guidelines. The EMA stated that, “CAT and CHMP members 
were involved in the preparation of the draft guideline through regular updates and the 
opportunity for comments at all milestones (e.g. draft to be released for public consultation). 
This guideline was presented to the CAT and CHMP for comments and adoption. The CAT 
and CHMP adopted the final version on 22 October 2009“ (j). 
4.2.3.3 Framing 
The immediate exclusion of the religious and ethical implications of xenotransplantation runs 
like a red thread through all published EMEA/EMA guidance documents. The topic of 
xenogeneic cell transplantation, though it has, e.g. serious legal implications concerning 
informed consent and surveillance, is only discussed in the context of sound science, i.e. 
                                                     
29 Xenogeneic cell therapy was defined in the document as “the use of viable animal somatic cell preparations 
suitably adapted for: (a) the transplantation/ implantation/ infusion into a human recipient or (b) extracorporeal 
treatment through bringing (non-human) animal cells into contact with human body fluids, tissues or organs” (EMEA 
2003: 3). 
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"proven quality, safety and efficacy“ (j: 3). Therefore, as EMA states: “Any guidance 
developed by the scientific committees of the EMA will therefore not address ethical or 
religious considerations, which are outside the remit of the EMA and which are the 
responsibility of the individual member states” (ibid.). 
4.2.3.4 Consultation 
Farrell (2009: 55) characterizes the regulation of cells and tissues within the EMA as “a 
largely technocratic-driven process (…) mediated by those with scientific expertise”. 
However, Regulation 1394/2007 also lays down two rules which could transcend a narrow 
technocratic decision making process: 
• The CAT is not only composed of members with a scientific background but also 
includes members representing patient organisations. In addition, it should include 
ethicists.30 
• Moreover, Regulation 1394/2007 established stakeholder involvement by declaring 
that, “open consultations with all interested parties, in particular member state 
authorities and the industry, have been carried out in order to capitalize on the 
limited expertise available in this area, and to ensure proportionality” (Regulation 
1394/2007: (21)). 
All scientific EMA guidelines are published on the EMA website as draft guidelines for public 
consultation. Both the 2003 as well as the 2009 document were open for public consultation, 
from November till May 2003 and February till August 2009, respectively. However, the 
documents do not provide any information on the result of the public consultations and in 
what way they were taken into consideration. 
Emanuele Cozzi et al. criticized the 2009 guidance document for failing “to address several 
important issues. These include the responsibility for conducting the xenotransplantation 
study according to the highest GCP31 standards, the definition of the long-term clinical 
surveillance of patients and their close contacts, sample archiving, the non-exclusion of 
paediatric subjects, and the absence of reference to xenotourism” (Cozzi et al. 2009: 209). 
The International Xenotransplantation Association commented on the EMA paper (d: 217-
220) but it is not clear how or whether this was taken into account because, on request, the 
                                                     
30 “The Committee for Advanced therapies should gather the best available expertise on advanced therapy 
medicinal products in the Community. The composition of the Committee for Advanced Therapies should ensure 
appropriate coverage of the scientific areas relevant for advanced therapies, including gene therapy, cell therapy, 
tissue engineering, medical devices, pharmacovigiliance and ethics. Patient associations and clinicians with 
scientific experience of advanced therapy medicinal products should also be represented” (Regulation 1394/2007: 
(11)) 
31 Good Clinical Practice 
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EMA stated that it received comments from three stakeholders in 2009 (j), the International 
Xenotransplantation Association not being among them.32 
Susana Borrás et. al. (2007: 593) described the systematic coordination of scientific inputs 
from different stakeholders of the EMEA’s decision as scarce and claimed that “information 
asymmetries in favour of industrial actors” were present in “highly technical regulatory areas, 
such as pharmaceuticals”, which would disfavour “groups that lack necessary cognitive 
resources to influence the policy process effectively”. Public participation would therefore be 
inadequate because the “authorization process comprises several formal and informal 
interactions between the agency and industry that are insulated from the public and other 
stakeholders” (ibid.). 
In summary, the procedures at the EMA are framed by sound science; ethical, legal and 
social aspects are deliberately excluded. The EMA does not carry out a discussion on such 
fundamental questions. On the contrary, the questions addressed are intended to give 
guidance to applicants for medicinal products and so very much downstream oriented. 
Although the guidance document emphasizes that it does not set a precedent for allowing 
clinical trials and authorizing products, it is nevertheless an important prerequisite for 
realizing xenotransplantation. The discussions on the guidance documents involved in-house 
experts and selected additional experts, as well as experts from other international 
organizations and the U.S. There was the opportunity for public consultations. However, 
within the research field of xenotransplantation, it is disputed whether all comments have 
been taken into account. Consultations were mainly used by expert and regulatory 
organisations.  
                                                     
32 These were: Medicines and Healthcare products Regulatory Agency (MHRA), the Paul-Ehrlich-Institute (PEI) and 
the Institute National de la Santé et de la Recherche Médicale. 
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5 Non-human Primates in Research 
5.1 Background 
A topic that has been widely discussed in relation to xenotransplantation is animal welfare 
and animal rights. It became relevant in the EU in the regulation of the use of non-human 
primates (NHP) for experimentation. Pig islet xenotransplantation is currently the most 
promising form of xenotransplantation but is still at a preclinical stage (Dominic 2005; 
Dufrane et al. 2006; Dufrane/Gianello 2008; Cozzi 2008). Adult porcine islets provide a 
source of insulin-producing cells and could be used in treating diabetes. For ethical and safe 
clinical trials to commence, more preclinical data is required. The pig-to-primate model is a 
necessary requirement for pig-to-human transplantation of islets to become a possibility. 
Nonhuman primates are also used as models in research on immunosuppression. 
5.2 Basic Process and Content 
On 25 September 2007, the European Parliament adopted a declaration urging the 
Commission and the Council of Ministers to end the use of apes and wild-caught monkeys 
and to establish a timeline to replace all non-human primates in scientific experiments 
(European Parliament 2007a, 2007b, Tallacchini/Beloucif 2009). The same year a group of 
European citizens sent a formal petition to EU Institutions, asking that experimentation on 
nonhuman primates be stopped (Tallacchini/Beloucif 2009). 
On 6 May 2008, the European Commission Environment Directorate General (DG ENV) 
responded by asking the Scientific Committee on Health and Environmental Risks (SCHER) 
to produce an opinion “on the possibilities to replace the use of non-human primates” in 
research (European Commission 2008a). The opinion should cover: 
1. areas of research and testing of products and devices, in which NHP are used 
today; 
2. currently available possibilities to replace their use; 
3. an outlook on replacement in the short, medium and long term by type of research 
and area of testing; 
4. opportunities for the reduction and refinement of their use, where no replacement 
seems possible in the medium term; 
5. the “Research areas which should be promoted to advance replacement, reduction 
and refinement of the use of non-human primates in scientific procedures” (SCHER 
2008c); 
6. implications for biomedical research in case of a ban on the use of NHP in the EU 
(c.f. ibid.). 
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Since this opinion, unlike the 2003 SCMPMD opinion (see chapter 2.1), was associated with 
current legislative activity, namely the revision of Directive 86/609/EEC, there was 
considerable time pressure to draft an opinion. The minutes state that the “scientific opinion 
would need to be available by the end of October 2008 to support the codecision procedures 
and the related discussions at the European Parliament and the Council” (European 
Commission 2008a: 3) 
The topic of NHP was on the SCHER’s agenda in five plenary and several working group 
meetings from May 2008 until January 2009. 
Following the rules of procedures for Scientific Committees, defined by the European 
Commission (2004: Article 7), the SCHER established a working group to draft its opinion. 
This group, comprising of Committee members and external experts, was recruited in a self-
selecting process.33 According to the rules of procedures, at least one working group 
member had to also be a Committee member. This person was also to hold the position of 
chair and was in charge of designating external members in consultation with the Scientific 
Committee (European Commission 2004: 7.2; 7.3). Recruitment of external experts was 
done in a dialogue between the DG SANCO, the Scientific Committees and the experts 
already identified (e: 66-70, 108-110). The working group contacted possible external 
experts and finally, as stated in the SCHER minutes, was able to cover “all the fields of 
expertise needed for the preparation of the opinion” (European Commission 2008c: 3). 
Throughout its existence, the working party met five to six times to draft the opinion (e: 154). 
On 13 January 2009, the SCHER finally adopted the paper (SCHER 2009). 
The SCHER strictly restricted its scope of analysis – in the same way as the SCMPMD and 
the EMA - to scientific questions, explicitly leaving out ethical, legal and social aspects of the 
use of NHP. The Opinion stated that, “the mandate for SCHER specifically excludes ethical, 
economic, cultural and social aspects of NHP use as this is dealt with by other groups within 
the EU Commission and the EU Parliament” (SCHER 2009: 7). The SCHER concluded that 
from a scientific point of view “developing and testing xenotransplantation methodologies” 
was one of four areas, in which “the use of NHPs, at the present time, is essential for 
scientific progress” (ibid. 21). It recognized that artificial organs, tissue engineering and stem 
cells might be alternatives to xenotransplantation but dismissed these alternatives for the 
time being because artificial organs would be “no alternative to organ transplantation” and 
“complex functions of organs such as the liver cannot yet be replicated” (ibid. 25). Stem cell 
and tissue engineering were regarded as “still in an early research stage and far away from 
                                                     
33 The final working group members included from SCHER Prof. W. Dekant (Chairman and Rapporteur), University 
of Würzburg and Dr. E. Testai, Instituto Superiore Sanità. External experts were: Dr. C. Bernardi, Preclinical 
Compliance Unit, Nervian Medical Sciences, Prof. C. Cavada, University of Madrid, Dr. D. Jones, EMEA Safety 
Working Party, Prof. D. Morton, University of Birmingham, Dr. E. Procyk, Stem Cell & Brain Research Institute, Prof. 
M. Spangberg, Swedish Institute for Infectious Diseases Control, Dr. C. Stark, Systemic and Reproduction 
Toxicology Unit, Bayer, Dr. J.W. van der Laan, EMEA Safety Working Party, Dr. K. Wickstrom, Medical Products 
Agency. 
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clinical applications” (ibid. 27). NHPs would therefore further be needed in 
xenotransplantation. Xenotransplantation was not the main focus of the paper but a 
“subordinated border area” (e: 135), which was brought into the working group by an 
external member (e: 100-101) 
5.3 Impact 
Already before the SCHER adopted the Opinion, the Commission published a proposal to 
revise Directive 86/609/EEC on 5 November 2008 (EC 2008). The aim of this proposal was 
to strengthen the protection of animals used in scientific experiments and to ensure their 
welfare. It also intended to ensure fair competition for industry and boost research activities 
in the European Union. In this proposal, the European Commission already determined that 
an outright ban on the use of animals in research was not possible. This statement was 
backed by an Opinion by the Commission’s Scientific Steering Committee published in 2002, 
which stated that NHP were needed in biomedical research. On 8 September 2010, the 
European Parliament adopted the new Directive, in agreement with the Council, to revise 
Directive 86/609/EEC on the protection of animals used for scientific purposes (Directive 
2010/63/EU). It acknowledged that animals, including NHP, were still needed for scientific 
research. 
5.4 Public Involvement 
In 2007, Pilot Dialogue Procedures introduced instruments for the incorporation of 
stakeholder input into scientific opinions (EC 2007). The aim was to “find the most effective 
means to interact with (…) stakeholders in an even handed and open way” (ibid. 1). The 
procedures specified in this Commission paper demonstrate the key challenges of 
stakeholder involvement in scientific committees as already pointed out in the previous 
chapters of this report: while public involvement is deemed necessary to implement the 
principles of “transparency, (…) openness and accountability”, the very involvement of 
stakeholders is considered as a threat to the routines of scientific committees. 
Firstly, stakeholder involvement exposes committees to public scrutiny, influence and even 
pressure. The Pilot Dialogue Procedures therefore emphasise that the independence of the 
scientific committee from “any influences” must be retained (ibid.). Stakeholders “must not 
(…) interfere with the internal work of the Committees, claiming a right or trying to be 
involved in such work or exerting pressures on Committee members” (ibid. 1ff.). Secondly, 
public involvement might change the framing of problems. However, the focus on scientific 
questions and sound science must be preserved. The objective of stakeholder consultations 
is therefore to “gather specific comments and suggestions on the scientific basis of the 
opinion, as well as any other relevant scientific information regarding the questions 
addressed, in order to allow the Scientific Committees to focus on issues which need to be 
further analysed” (ibid. 8, emphasis added). In order to be able to put forward their 
I H S — Griessler et al. / The Challenge of Public Participation in a Multilevel System — 34 
 
comments, stakeholders therefore have to follow strict requirements regarding format and 
content, otherwise their comments are dismissed. A further factor restricting stakeholder 
involvement, as defined in the Pilot Dialogue Procedures, is that involvement does not 
necessarily mean dialogue and accountability. The Scientific Committee does not respond to 
the comments (ibid. 9). Furthermore, no reports are foreseen to document consultation 
processes for stakeholders (ibid.). 
Stakeholders can be involved at different stages of a scientific opinion. They can: 
• suggest new topics, which the Commission may consider to submit to a Scientific 
Committee, 
• contribute to the finalisation of new mandates, 
• respond to calls for data and information and/or provide scientific input during the 
preparation of the Opinion, 
• participate in public consultations on preliminary reports, and/or 
• submit scientific comments on existing opinions (c.f. ibid. 2). 
During the drafting of the Opinion on NHP, a public consultation on the working mandate and 
a public hearing were carried out to involve the public. 
5.4.1 Public Consultation on the Working Mandate 
According to the European Commission, “the Scientific Committee may decide to submit its 
opinion to a public consultation where the Committee and Commission decide that it would 
enhance the quality of the work. In this case, a preliminary opinion, allowing comments from 
interested parties and other stakeholders, within a set deadline, will be published on the 
Commission’s website. The Scientific Committee will take account of the comments received 
when adopting its final opinion” (European Commission 2004: 23.c.). 
The minutes of the SCHER’s 23rd plenary meeting mentioned that a public hearing on the 
working mandate was envisaged to take place from 15 May to 6 June 2008. On the 
SCHER’s website, the European Commission published a “Call for information” for a “Public 
Consultation on 'working mandate' and call for the submission of information or data on the 
need for non-human primates in biomedical research, production and testing of products and 
devices” (SCHER 2008a, emphasis in the original). The call included a link to the working 
mandate (SCHER 2008c), the Pilot Dialogue Procedures (EC 2007a) and Guidelines for 
Submissions (N.N.: w. d. a). It provided information on the DG ENV’s request for an Opinion 
and invited interested parties to submit scientific contributions by 6 June 2008  (SCHER 
2008a). These contributions included: 
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1) “Scientific peer reviewed research papers, reviews and reports (later than 1990) on test, 
methodology and possible alternatives related to the use of non-human primates in 
biomedical research, production and testing of products and devices 
2) Other credible scientific information that may not be easily available and which is directly 
relevant to this issue” (SCHER 2008a). 
Thus the call made it very clear that the contributions should only cover “credible scientific 
information”. Whether the SCHER took contributions into consideration depended on several 
strict criteria: 
1. “it is directly referring to the content of the report and relating to the issues that the 
report addresses, 
2. it contains specific comments and suggestions on the scientific basis of the opinion, 
3. it refers to peer-reviewed literature published in English, the working language of 
SCHER and the working group, 
4. it has the potential to add to the mandate and the opinion of SCHER” (SCHER 2009: 
37). 
The minutes of the SCHER’s 24th plenary meeting, held in Brussels on 15 July 2008, gave a 
very brief account on the public consultation, revealing only that the consultation was held 
and that “around 700 scientific articles and 140 comments were received”.34 It was 
mentioned that the working group would review these contributions. The consultation also 
had actual implications for the working group, since the records state that more external 
experts would be needed “to cover some points of the request” (European Commission 
2008b). 
5.4.2 Public Hearing 
At SCHER’s 24th Plenary Meeting, the working group and the Commission recognized that 
the opinion had to be prepared within a “tight deadline” and decided not to “proceed with a 
public consultation on this very sensitive issue” but instead “organize at least a public 
hearing on the use of non human primates in research” in November 2008 (SCHER 2008b: 
3ff.). 
This public hearing, at which the draft opinion was subject to discussion, took place on 6 
November 2008. To be eligible for participation, interested stakeholders were required to be 
scientists or technical experts with expertise in the field and to identify a particular subject 
matter they wished to address with appropriate scientific evidence relevant to the subject 
(SCHER 2008b). The call for participation states that, “when submitting their application, 
                                                     
34 The Opinion gives the exact numbers with 628 scientific articles and 84 comments received “from non 
governmental organizations, industry, academia, public authorities and individuals” (SCHER 2009). 
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potential participants should provide full professional details, specify the particular topic they 
wish to address in the hearing giving technical justification for their request” (ibid.). Also, the 
number of participants was limited to “two representatives for each registered organization” 
(ibid.) due to space restrictions. The Commission services and the SCHER selected 
participants according to certain criteria: 
• “Based on the technical justification provided, the participant is expected to provide 
scientific evidence with a relevance to the subject; 
• Interested participants have clearly identified the subject matter they would wish to 
address and have provided sufficient technical justification; 
• Interested participants are scientists or technical experts with an appropriate 
expertise in the field who are able to appropriately present and understand the 
scientific arguments” (SCHER 2008b). 
In the meeting itself, 48 representatives of various stakeholders including academia, NGOs, 
industry, and governmental institutions participated (N.N.: w. d. b). There was little 
information available about the meeting except a short, 5-line report, which only stated that 
“the outcome of the discussion together with material submitted subsequently, were 
considered in the final opinion” (ibid. see also SCHER 2009: 37). 
As a consequence of the hearing, two working group meetings were planned to enable the 
working group “to go through to the contributions received by stakeholder participating in the 
hearing” (European Commission 2008d). The final Opinion stated that, “each submission 
which met (the) criteria has been carefully considered by the Working Group. The scientific 
rationale of the opinion has been revised to take into account relevant comments and the 
literature has been updated with relevant publications” (SCHER 2009). 
Nevertheless, an animal rights’ NGO, the European Coalition on the End of Animal 
Experiments (ECEAE), who, according to their Website, participated in both the consultation 
and the hearing, contested the Opinion (ECEAE 2009). They forwarded a complaint with the 
Ombudsman of the EU claiming that the working group did not have enough expertise in the 
area of NHP research and did not take into account the latest scientific evidence and 
statements made by interest groups on alternatives to NHP research. The ECEAE 
challenged the Opinion with scientific arguments, contesting the Committee’s adequacy and 
the completeness of the scientific evidence considered (ibid.). 
5.5 Summary 
During the course of approximately a decade, the European Commission introduced a 
number of measures to increase transparency, independence and excellence of its scientific 
committees. 
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• In principle, stakeholders can suggest new topics, “which the Commission may 
consider to submit to a Scientific Committee” (European Commission 2004: 2). This 
was not the case in the Opinion on NHP; the topic was raised by the European 
Parliament and by petitions of European citizens (European Commission 2007). 
• Several documents were made available on the Internet (European Commission 
2004: 5.3.). Inter alia the minutes of plenary minutes are published. They included a 
list of participants, declarations of interest, adopted agenda “summary of discussion, 
including important minority stand points and agreed actions”, “a record of decisions 
taken and opinions adopted” and abstentions during voting (European Commission 
2004: 21). 
• Moreover, active stakeholder involvement is organized; during a consultation phase 
and public hearing, NGOs were able to comment on the working mandate and the 
draft opinion. 
• NGOs were able to send a complaint to the European Ombudsman. 
However certain factors limited transparency and openness: 
• Requests for an Opinion have to come from the Commission (European 
Commission 2004: 13). The Scientific Committee can raise issues and it is up to the 
Commission to decide which action to take including “a request for a scientific 
opinion or a report on the matter” (ibid. 16.2).  
• Recruitment of a working party is clearly a self-selecting process (e: 286, “the group 
co-opts itself”) (c.f. also European Commission 2004: 7). Access to committees is 
restricted to scientists. However, as a consequence of the public consultation, more 
experts were needed. 
• The work of the Scientific Committee was strictly framed and confined by sound 
science. ELSA aspects were explicitly excluded. Participants who wanted to 
contribute to the debate had to follow this framing and were otherwise denied 
access. 
• The discussion within plenary and working group meetings is not public and 
committee members are bound by confidentiality. The rules of procedure determine 
that “individual views, whether expressed orally or in writing by members, associated 
members and external experts during deliberations within the Scientific Committee 
or a Working Group shall be confidential” (European Commission 2004: 12.3.). 
• In order to be accepted as participants in a public hearing and consultation, strict 
requirements had to be met in terms of format and content of contributions. 
Moreover, the number of participants was restricted. 
• Although the SCHER claimed that stakeholder comments contributed to the Opinion, 
it is completely unclear in what way and to what extent this happened, since the 
scientific commission is not obliged to reveal this information. 
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6 Funding Research 
The EU was not only active in regulating but since 1997 also in funding xenotransplantation 
research. In total, thirteen projects were identified that received funding in the Fifth, Sixth and 
Seventh Framework Programmes (see Table 2 to 5). Most of the projects were genuine 
xenotransplantation research but several of them dealt with xenotransplantation from an 
ELSA perspective. Many projects were rather small individual fellowship grants but there 
was also a series of financially more substantial, integrated projects, such as: 
• “Xenotransplantation – strategies for the prevention of carbohydrate related 
(hyperacute) rejection”35 
• “Pathogenesis, epidemiology, immunopathology, and diagnosis of post-weaning 
multisystemic wasting syndrome (PWMS): an emerging disease of swine due to new 
porcine circovirus (PCV2). Development of recombinant vaccines” 
• “Engineering of the porcine genome for xeno studies in primates: a step towards 
clinical application (XENOME)” 
The Commission’s general rationale for funding health related research is to improve both 
the health of Europeans as well as the economic position of Europe; it was described by an 
interviewee as intended "to improve quality of life and health of the citizens and to improve 
the competitiveness of the European industry" (g: 257-258). Xenotransplantation was funded 
under the heading of "new therapies" (g: 16), which includes "non-pharmaceutical cell based 
therapies, tissue engineering, gene therapy, regenerative medicine (...) human embryonic 
stem cells, stem cells" (ibid. 17-19). Public funding in this area is considered justified if 
several conditions are met; these include cases where new therapies (a) would have a high 
potential to cure life threatening, currently incurable diseases; (b) they would be at a very 
early stage of development, and, (c) although they would be risky there would be "proof of 
principle", mostly in animal models, that research therein was "worth trying" (c.f. g: 16-26). 
Within the "wider program" of new therapies, xenotransplantation was described by an 
interviewee as one of several "routes" to alleviate organ shortage, amongst treatment of 
diseases leading to organ failure, regenerative medicine, and artificial organs (g: 36-41; 48-
56; 99-102). After a "hiatus" (g: 64) of funding, stimulated by a concern about porcine 
endogenous retroviruses (PERV) and potential cross-species infection, in 2006 the 
European Commission started funding the integrated project XENOME, which looks at solid 
organ and cellular xenotransplantation. The fact that the risk of cross infection was no longer 
regarded as an issue necessarily blocking research encouraged this renewed interest. (g: 
68-70). XENOME is “the principle European effort in the field of xenotransplantation” (Stein 
2010: 13). Commissioner Geoghegan-Quiinn referred to the project as “the reference for 
                                                     
35 For a detailed description of this research project, which also involved researchers from the social sciences and 
humanities to address ELSA of xenotransplantation see the Case Study on Sweden within the CIT-PART project 
(Hansson/Lundin 2011). 
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European efforts in xenotransplantation research, with islet and neural cells representing the 
areas with greatest potential to take towards the clinics” (E-9429/2010).36 
The European Commission also funded a number of projects, which dealt with ELSA of 
xenotransplantation: 
• The project “Xenotransplantation: ethical, social, economical and legal aspects” 
provided an overview on ELSA in this area as well as on international regulation 
(Jansen/Simon 2008a, 2008b, 2008c, 2008d, 2010). 
• The project “Increasing Public Involvement in Debates on Ethical Questions of 
Xenotransplantation (XENO)” aimed at improving stakeholder debates in ELSA of 
xenotransplantation (Griessler/Littig 2003, 2006). Evaluators recommended this 
project because they considered xenotransplantation as “a growing issue” in which 
“more and more public concern about the use of (…) animal-parts in medical 
treatment“(h: 44-46) could occur. 
• DECIDE, a project in which laypeople are informed in a game setting about and 
discuss diverse controversial technologies, also includes xenotransplantation as a 
topic.37 
• CIT-PART, of which this report is part of, can also be considered as an ELSA project 
in this area. 
These projects received funding under the “Science and Society” Programme but with two 
exceptions, as it was renamed “Science in Society”. Their funding is based on a model of 
citizen participation that departs from that of the scientific advisory system, described in 
earlier chapters. Drawing on GMO as a text book case for a technology which caused public 
resistance and political crisis, these programmes, in order to avoid such intractable 
confrontation, emphasise early engagement with the public, participatory technology 
assessment (h: 12-14)38, mobilization and mutual learning actions39 (h: 79-80) as well as 
responsible research and innovation. 
An interviewee perceived the GMO case as an example of a technology in which scientists 
and policy makers did not take into account that “public opinion might not like a 
technologically attractive solution” (h: 74). This attitude caused “huge problems with protests 
                                                     
36 XENOME addressed in one work package also ELSA http://www.xenome.eu/ (accessed: 24/1/2012). 
37 www.playdecide.eu/play/topics/xenotransplantation (accessed: 27/1/2012). 
38 An example for several projects funded by the European Commission in this area is the current PACITA project. 
www.pacitaproject.eu/?page_id=506 (accessed: 1/2/12); another one the Meeting of Minds - European Citizens' 
Deliberation on Brain Science, http://www.meetingmindseurope.org/europe_default_site.aspx?SGREF=14 
(accessed: 27/1/2012). 
39 One example is the currently funded GAP2 project “Bridging the gap between science, stakeholders and policy-
makers”. 
cordis.europa.eu/fetch?CALLER=FP7_PROJ_EN&ACTION=D&DOC=51&CAT=PROJ&QUERY=012cee69e58c:4c1
2:3b6f8b90&RCN=99712 (accessed: 27/1/2012). 
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and people tearing up fields and so forth” (ibid. 76-77). Early engagement with the public, as 
a strategy intended to resolve such conflicts, would require seeing “what the issues are as 
soon as possible” (ibid. 57). As the interviewee clarified, “the rationale is try to involve 
stakeholders and interested parties at the time research agendas are drawn up, so that’s 
instead of doing the research, develop the technology and then rolling it out and then finding 
out that you have got hostility from stakeholder-groups” (ibid. 81-84). Early engagement 
should “create a win-win-situation by involving all parties from the outset” (ibid. 85). This 
approach may lead to different technological solutions: “It may well be that the original 
research based agenda might not be the same that is adopted after this process, it may be 
modified, but if you modify (…), what was originally thought to be a good idea, you avoid 
impasses or total hostility and that’s pretty in (…) everyone’s interest” (ibid. 86-89). Early 
engagement is considered, as described by another interviewee, as a means of avoiding a 
blockage: “if things are developing without contact between these various factors you end up 
in a situation where there is a point of no return. You know because you have invested a lot 
in one direction you know just to drop it or to go back, so it’s a bit guerre de tranchées, 
nobody can progress when it is like that, very early if you succeed to have time of co-
construction of research agenda and co-construction of a common vision for common future 
then it becomes more easy, it is much easier to develop things without too much 
misunderstanding” (i: 69.75). Nanotechnology, stem cell technology, nanoparticles in 
consumer products, and synthetic biology would all be examples for technological areas 
“where there may be very good grounds for canvassing public opinion and understand 
what’s involved” (h: 60-61). However, involving the public would not be about getting it “to 
blindly accept new technological developments but it was to find ways of creating a channel 
through which the public could start to express its opinion, positive or negative, on the 
development of emerging technologies” (ibid. 48-50).40 
In contrast to the so called deficit model, the idea of early engagement is based on a concept 
of public, in which, as an interviewee made clear, laypeople are not to be converted or 
educated but listened to: “the public isn’t just an empty vessel waiting to be filled with 
scientific information and they would passively accept it. (…) It was realized that scientists 
need, or needed and still need, to be much more aware of how the public thinks, because 
the public is not trained to think in a scientific way. Nonetheless, that does not mean that 
their way (of) thinking is in any way inferior and sometimes scientists forget that. What might 
be an interesting scientific solution to a problem might be totally morally and ethically 
unacceptable, and therefore it is advantageous for scientists to know about these issues, 
and before they try to seek public money to fund, or any money to fund projects and then 
identify that (…) the work that they have done (…) attracts hostility. And therefore the 
objective of that call (in which the project XENO got funded, EG) is to try to bring the scientist 
and the public together in a two-way communication-process” (ibid. 178-189).  
                                                     
40 For the different approaches of citizen involvement as public relation or actual participation see also the OECD 
case study. 
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Table 2: FP4 1994 – 1998 
Project Duration EC Contribution 
in Euro 
Lead Country Program Contract Type Number Link 
Installation of a European 
Centralized Facility for 
Preclinical Evaluation of 
Immunotherapy in 
Nonhuman Primates 
1996-1998 n.a. Netherlands BIOMED2 Coordination of 
research actions 
BMH4960127 http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_LAN
G=EN&PJ_RCN=2
683329&pid=0&q=6
2447073E8D4A383
BA85C17696FB2F
7D&type=sim  
Xenotransplantation – 
strategies for the 
prevention of carbohydrate 
related (hyperacute) 
rejection 
1997-2000 1.500.000 Sweden BIOTECH2 n.a. BIO4972242 http://ec.europa.eu/
research/biotech/bi
otech2-vol3/5-1-05-
sub_en.html  
Characterization of porcine 
complement regulatory 
molecules; application to 
xeno 
1998-2000 n.a. UK Training and 
Mobility of 
Researchers 
post-doctoral 
research training 
grants 
FMBI972590 http://cordis.europa.
eu/tmr/src/grants/f
mbi/972590.htm 
Xenotransplantation: 
ethical, social, economic 
and legal aspects 
1998-2000 n.a. Germany BIOTECH2 ELSA BIO4-CT98-
0512 
http://ec.europa.eu/
research/biosociety
/research_projects/
xenotransplantation
_en.htm 
Glycoimmunology: 
synthesis and biological 
activity of immunoreactive 
glycocojugates 
1996-1998 n.a. Netherlands BIOTECH2 Coordination of 
research actions 
BIO4950004 http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_LAN
G=EN&PJ_RCN=2
901296&pid=0&q=
B284DAAAEE416F
50BA7A89DABA16
9838&type=sim 
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Table 3: FP5 1998 - 2002 
Projects Duration EC Contribution 
in Euro 
Lead Country Program Contract Type Number Link 
Establishment of novel 
targets for risk assessment 
and monitoring of 
xenogeneic infections in 
the course of animal to 
human transplantation 
(XENODIAGNOSTICS) 
1999-2000 25,000 Germany LIFE QUALITY Exploratory 
awards 
QLK2-CT-1999-
40210 
http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_RC
N=4673365&CFID=
8981167&CFTOKE
N=51089429 
Pathogenesis, 
epidemiology, 
immunopathology, and 
diagnosis of post-weaning 
multisystemic wasting 
syndrome (PWMS): an 
emerging disease of swine 
due to new porcine 
circovirus (PCV2). 
Development of 
recombinant vaccines 
2000-2003 1,199,467 Spain LIFE QUALITY RS QLK2-CT-1999-
00307 
http://cordis.europa.
eu/life/src/control/ql
k2-ct-1999-
00307.htm 
Study of the adhesive 
interaction between human 
and pig cells via daf/cd97; 
significance in 
xenotransplantation 
2000-2001 54,504 Spain LIFE QUALITY Research grants 
(individual 
fellowships) 
QLK3-CT-1999-
51523 
http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_RC
N=5098258 
Increasing public 
involvement in debates on 
ethical questions of 
xenotransplantation 
(XENO) 
2002-2004 245,500 Austria HUMAN 
POTENTIAL 
Preparatory, 
accompanying 
and support 
measures 
HPRP-CT-2001-
00013 
http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_RC
N=5317361 
Establishment of novel 
targets for risk assessment 
and monitoring of 
xenogeneic infections in 
the course of animal to 
human transplantation 
(XENODIAGNOSTICS) 
2002-2004 262,000 Germany LIFE QUALITY Cooperative 
research 
contracts 
QLK2-CT-2002-
70785 
http://cordis.europa.
eu/search/index.cf
m?fuseaction=proj.
document&PJ_RC
N=5699418 
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Table 4: FP6 2002 - 2006 
Projects Duration EC contribution in 
Euro 
Lead Country Program Contract Type Number  Link 
Engineering of the 
porcine genome for 
xeno studies in 
primates: a step 
towards clinical 
application 
(XENOME) 
2006-2011 9,880,000 Italy LIFESCIHEALTH Integrated Project 37377 http://cordis.europa.
eu/fetch?CALLER=
FP6_PROJ&ACTIO
N=D&DOC=1&CAT
=PROJ&QUERY=0
12641d6a67c:7c77:
3d09bbdc&RCN=8
4970 
Study of the 
CD200/CD200R 
pathway in the pig-
to-human setting to 
elucidate the 
molecular bases of 
xenograft rejection 
and develop 
approaches that 
promote xenograft 
survival 
(PORCINE 
CD200) 
2006-2008 80,000 Spain Marie Curie actions Human Resources 
And Mobility 
21293 http://cordis.europa.
eu/fetch?CALLER=
FP6_PROJ&ACTIO
N=D&DOC=1&CAT
=PROJ&QUERY=0
12c310fb8d5:e152:
7da5f1e0&RCN=79
038 
Table 5: FP7 2007 - 2013 
Projects Duration EC Contribution in 
Euro 
Lead Country Program Contract Type Number Link 
Impact of citizen 
participation on 
decision-making in 
a knowledge 
intensive policy 
field (CIT PART) 
2009-2012 1,000,000 Austria SSH Small or medium-
scale focused 
research project 
225327 http://cordis.europa.
eu/fetch?CALLER=
FP7_PROJ_EN&Q
Z_WEBSRCH=SS
H&QM_EP_PGA_A
=FP7-
SSH&QM_EP_SPA
_A=SSH-2007-5.1-
01&QM_EN_OC_A
=&USR_SORT=EN
_QVD+CHAR+DES
C 
 
I H S — Griessler et al. / The Challenge of Public Participation in a Multilevel System — 44 
 
7 Conclusions 
This case study covers EU xenotransplantation policy from 1997 until 2009. In this period 
xenotransplantation was not subject to as fierce of a public dispute and scrutiny at the 
European level as other areas of biotechnology and biomedicine such as, e.g., GMO, BSE or 
human embryonic stem cells. On the contrary, the few accessible documents tell no story of 
controversy. The European Parliament did not debate the issue at any length. Only a handful 
of Members of Parliament addressed the subject in a few parliamentary questions.1 The 
European Council briefly discussed xenotransplantation in the context of the clinical trials 
Directive.2 Two scientific committees of the Commission, the SCMPMD and the SCHER 
dealt with the issue in their opinions. In addition, the Commission funded xenotransplantation 
research and ELSA projects in its successive Framework Programmes. The EMEA/EMA 
issued guidelines for xenogeneic cell based products in the 2000s. 
In general, EU xenotransplantation policies can be characterized as enabling. The SCMPMD 
opinion was cautious but overall positive and framed xenotransplantation as one possible 
solution to organ shortage, mainly in cellular xenotransplantation. The clinical trial Directive 
established a compromise, which did not block clinical research altogether and left it to 
Member States to choose their own policies, thereby, in principle, allowing them to postpone 
decisions on clinical trials indefinitely. The European Council as well as the European 
Parliament and several of its Committees were involved in the codecision process, which led 
to this Directive. After this decision, EU policies became increasingly downstream and 
application oriented as well as technical. As Tallacchini observed, “the EU seem to be 
moving far from their former, more precautionary, position on (xenotransplantation), and to 
be adopting a more open view on the topic” (2002: 372). Rather than discussing “a 
moratorium on all clinical experimentation”, the focus moved towards “careful transnational 
monitoring, surveillance, and harmonization of standards” (ibid.). Consequently the 
EMEA/EMA established two documents, which defined standards providing guidance for 
potential applicants of market authorization; these reached throughout the entire 
xenotransplantation process, from animal rearing and husbandry to surveillance of human 
recipients, their close relatives and medical staff. The SCHER also contributed to the 
realization of xenotransplantation research by recognizing it as an area in which the use of 
NHP was deemed necessary. In addition, the European Commission actively supported 
xenotransplantation by funding it under the heading of “new therapies”. However, it also 
funded research in ELSA and participatory experiments therein. The public, however, was 
                                                     
1 On 16 July 1997 Commissioner Cresson responded, for example, to a written Parliamentary question posed by 
Hiltrud Breyer whether the Commission would fund xenotransplantation research (E-1467/96) that no research was 
currently being carried out. The short response continues, however, that this does not “rule out such research in the 
future, as heterotransplantation is part of the work programme of research into medical bioethics”. 
2 The Swedish Presidency organized on 11 - 12 June 2001 together with the European Commission a conference 
on „Ethics and biomedical research – the process of balancing benefits and risks“ in Umea, Sweden. One of the 
three examples discussed at the conference was xenotransplantation. Xenotransplantation researchers as well 
bioethicists and a representative of a animal welfare organization gave presentations. 
I H S — Griessler et al. / The Challenge of Public Participation in a Multilevel System — 45 
 
almost entirely absent in advisory and decision making processes leading to these policies, 
except for the SCHER’s public consultation and hearing on the use of NHP in research in 
2008. 
Xenotransplantation was mostly put on the political agenda by scientific experts. The 
SCMPMD brought the topic to the Commission’s attention as a future issue worthy of 
analysis. The EMEA/EMA dealt with xenotransplantation because it perceived regulatory 
gaps and recognized that firms were already developing products including xenogeneic cells. 
In contrast, the revision of a Directive on the use of NHP was put on the Commission’s 
agenda by citizen’s petitions and a European Parliament declaration. The topic of 
xenotransplantation was raised in this context by an external member of SCHER, but was 
only considered as a subordinated boundary area. 
The limited xenotransplantation discussion at the EU level was mainly framed by organ 
shortage, the potentially associated risk of cross-species infection and how to contain it. 
Animal welfare was mainly discussed in the context of the use of NHP in research and 
proper breeding and husbandry. 
The focus of discussion was strictly limited by the notion of sound science. In other words, 
though the available documents regularly acknowledge the validity of ethical issues, they 
exclude them with the very same regularity from the scope of their analysis and pass them 
on to other bodies, which are never clearly identified. The documents do not discuss the 
ethical acceptability of xenotransplantation in principle and hardly address the issue of public 
participation. Instead they take for granted that xenotransplantation is in principle ethically 
acceptable. As a consequence ethical, legal and social aspects were never comprehensively 
addressed by an advisory body of the Commission. However, they were addressed in 
several Commission funded research projects and participatory experiments. Yet, it seems 
that these were insufficiently linked to the Commission’s advisory system and to decision 
making in the European Institutions. 
The main everyday routines of policy making identified were procedures within the 
codecision process between the European Institutions and the European Commission’s 
organized scientific advisory system. This process mainly becomes visible in official 
documents available at PreLex. 
The European Commission exclusively used expert TA to get information and advice for its 
xenotransplantation policies. The impact of TA differed according to scientific body. The 
SCMPMD raised xenotransplantation on its own initiative without connection to a legislative 
activity; consequently it only had limited impact on policy making. In contrast, Borrás et al. 
consider the impact of the EMEA/EMA decisions as substantial overall (2007). The 
Commission’s decision on the use of NHP in research was made before the final opinion 
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was adopted by the SCHER. However, the Opinion was in line with the Commission’s 
general policy. 
Although the European Union called for increasing citizen participation (Commission of the 
European Communities 2001, Abels 2002, Griessler 2011), the whole observable regulation 
process was, as has already been said, distinctly expert oriented. The working procedures of 
scientific bodies left little room for citizen participation. Citizen involvement was limited to the 
provision of well-measured information and a very strictly regulated and framed public 
consultation and hearing, which did not provide opportunities to raise questions on the ELSA 
of xenotransplantation. 
The EU did not apply the tools of public consultation and citizen involvement in 
xenotransplantation policy making. As Tallacchini observed, the rhetoric of citizen 
participation remained “more (…) an intellectual exercise” (Tallacchini 2008:162). Citizens 
were defined as a lay public, stakeholders, patients and consumers and mostly excluded as 
active actors in policy making. Furthermore, citizens were allowed to retrieve provided 
information from the Internet and only admitted to public consultations and hearings if they 
accepted to ask purely scientific questions. Yet an animal welfare organization contested this 
narrow definition. The European Coalition to End Animal Experiments participated in 
SCHER’s public consultation and hearing, challenged SCHER’s expertise on animal welfare 
issues in regards to the research on NHP and entered a formal complaint to the European 
Ombudsman. 
Participatory experiments, as already mentioned, were limited to research projects funded by 
the European Commission. During the last decade, PTA became a well-established method 
within the “Science in Society” program, which developed from methodological experiments 
into integrated projects, which emphasize mobilization and mutual learning of stakeholders in 
research and innovation. However, in the case of xenotransplantation there was no 
connection between these participatory experiments and actual advice and policy making in 
scientific committees and political bodies. 
In recent years, the European Commission took several important measures to strengthen 
public trust in its regulation by emphasizing and increasing the independence, excellence 
and transparency of its scientific advisory committees. As a consequence the SCMPMD, 
EMA/EMEA and SCHER provided well-measured public involvement by allowing limited 
access to information, public consultations and hearings. Although the opening of scientific 
committees was a positive and significant step towards transparency and citizen 
participation, several important restrictions to citizen involvement in scientific committees 
exist and the power asymmetry between experts and laypeople is still enormously strong in 
favor of the former. Several factors are important in this context: 
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Xenotransplantation is a complex, transdisciplinary problem with repercussions, as has been 
shown, in many policy fields. The handling of such problems requires adequate complexity 
within an organization and therefore involves many internal and external actors. This turns 
citizen participation into a difficult problem and a substantial challenge for national 
governments. However, the task becomes even more difficult in the EU context with its multi-
level system of governance and the different roles of the European Institutions therein. This 
not only poses an enormous challenge for European Institutions but also for European 
citizens. The number and complexity of EU Institutions, agencies and advisory bodies 
involved in xenotransplantation policies and their relation to one another appears to 
outsiders as an impenetrable labyrinth. Interested citizens would have to find out, e.g.: Who 
is competent for what in which area? When, where and how do important negotiations and 
decisions take place? Therefore it is very difficult for outsiders to keep track of, where and 
when, what consultations are carried out. This opaqueness, due to sheer complexity, poses 
a serious impediment for citizen participation. 
Another problem concerns transparency. Although a number of quite successful attempts 
were made to increase transparency (e.g., by providing minutes, reports, decisions, 
information about expert recruitment), the insulation of the European Commission and the 
limited information it provides to outsiders still pose restrictions to transparency and citizen 
participation because available documents from European Commission Service, The 
Parliament, The Council, and scientific committees such as e.g., minutes, are often brief and 
do not provide much information to outsiders. Mostly they only inform about results of 
negotiations, not about the different positions actors were taking and the policy making 
process itself. European Council documents to which the public has access, e.g., do not 
justify a policy and do not explain why Member States decide to vote in a particular way. The 
tendency for insulation was more pronounced within the European Commission than in 
several other bureaucracies investigated in the CIT-PART project. Some interview requests 
to Commission staff and Members of Parliament were either denied altogether or were partly 
of limited value because civil servants of the European Commission are bound by 
confidentiality. This obligation also applies to members of scientific committees. Though 
understandable in relation to patent interests, this obligation also impedes citizen 
involvement and poses a severe methodological hindrance on social science research. 
Citizen participation is also difficult to achieve because routine practices of scientific 
committees mainly take into account scientific experts. Once selected as members of a 
scientific committee, scientific experts make most of the important decisions such as 
recruiting working groups in a self selecting process, putting topics on the agenda, framing 
questions, consulting with the public, as well as drawing conclusions thereof. 
Expert members of scientific committees in general are also in an advantageous position in 
comparison to citizens and NGO representatives because their activity in scientific 
committees is often part of their normal professional activity and supported by their 
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employees. In contrast, stakeholder representatives and citizens often lack the necessary 
funding to regularly participate in consultations and hearings. 
This is connected to another problem citizen participation is facing currently, that is the strict 
framing of what is considered a valid problem in public consultation and public hearing 
according to the criteria of sound science. The focus on downstream oriented and exclusion 
of ethical questions, limits the scope of questions that can be discussed. According to an 
interviewee, stakeholder involvement would be problematic because it would bring conflicts 
of opposing groups into scientific committees, which cannot be solved by scientific methods 
(b: 235-242). However, these are also the sorts of questions, which are of concern to 
citizens. In addition, strict administrative requirements for public consultations and hearings 
turn public participation into a rather exclusive activity. Gender related problems were also 
never addressed in the documents. 
Another problem public participation was facing is a lack of transparency of how the input of 
public consultations and hearings was dealt with. Citizens are currently not informed about 
the impact of their contributions on an opinion. 
However, the perspective on public involvement is nothing but uniform within the European 
Commission. On the contrary, a diversity of policies seems to coexist regarding the 
challenge of citizen participation in science and technology policy. Whereas the routine 
practices within scientific committees and the codecision process were only participatory to a 
very small degree, the „Science in Society” Program advocated early involvement and 
engagement with the public. The European Commission funded research, which 
experimented with participation in science and technology policy. These activities, however, 
appeared to be rather disconnected from the scientific advisory system and decision-making 
in xenotransplantation policies. In summary, European xenotransplantation policies were 
directed towards safe implementation of the technology, whereas ELSA of 
xenotransplantation were hardly addressed. Public participation in xenotransplantation 
policies was discussed and experimented with, however, never actually applied in policy 
making.  
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8 Appendix 
8.1 Political System 
Legislature and Constitutional Division of Territorial Power: 
The political system of the European Union (EU) is exceedingly complex because it is a 
multilevel system featuring a number of institutional actors and procedural routines 
functioning at each of its several levels. In order to deal with the task of coordinating the 
different levels, the EU quickly developed the principle of subsidiarity, i.e. the level where a 
problem arises should ideally also be responsible for solving the problem. 
At the lowest level of policy making, communes and regions are represented in the EU 
Committee of Regions. As with all other institutional features of the EU, this does not prevent 
the actors who are represented in a certain institution from being simultaneously engaged in 
other institutions. In the case of the communes and regions, actors also contact the 
Commission directly in earlier and Parliament and national governments in later stages of 
the policy process. To this end, many regions (e.g. all nine Austrian ones) have a permanent 
representation in Brussels. 
At the national level, most institutions important in the member states also make an effort to 
have their interests represented at the EU level also. In contrast to the representation of EU 
policy making in the mass media, national governments often do not speak with one voice in 
Brussels. Nevertheless, the most important institution representing national interests at the 
EU level is the European Council. 
The Council of the European Union (commonly known as the Council of Ministers) has 
executive and legislative functions and is the EU’s primary decision-making body; it is 
empowered to make decisions on any topic. However, it cannot propose laws, as this is the 
Commission’s task. It is an institution that both defends national interests and acts as a 
collective system of decision-making. Its members are usually ministers from the member 
states. The Council has nine different configurations; depending on what policy issue is 
discussed, different ministers attend the meetings. Permanent representatives prepare the 
meetings and much of the work within the Council is done by them: by COREPER (Comité 
des représentants permanents) and by approximately 250 working groups that assist 
COREPER. All in all, the Council involves a great number of national officials, who meet at 
the level of the ministers’ council, COREPER and at working group level. 
The EU political system features, besides the Council of the European Union, also a second 
chamber, the European Parliament, of which the Council is the more powerful one. 
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The European Parliament is the only directly elected EU institution. It has  
• supervisory power: it can supervise the Commission (rights to question, comment on 
and debate on reports) and to a more limited extent the Council (through assent),  
• legislative powers: most of the decision-making today follows the codecision-
procedure, 
• and budgetary powers. 
All of these powers have increased with each treaty. Especially the treaty of Lisbon 
strengthened the Parliament’s role as the codecision procedure has since been extended to 
almost all policy areas. As in the US, detailed work is carried out by standing committees 
(Bomberg/Stubb 2008: 59) of which there are currently 20.3 These are set up to prepare 
work for plenary sittings that are organized by policy area. The committees undertake (1) 
legislative work by analyzing draft legislations and writing amendments and (2) oversight 
activities. Each committee has a chairman, three vice chairmen and a Rapporteur, who is 
responsible for drafting the committee’s Opinion or report. Committees provide the 
opportunity for individual members to have an impact on policies (Scully 2007:182). 
The European Commission, the European Parliament and the Council of the European 
Union make the European Union’s decisions. In principle, it is the Commission that proposes 
new laws but it is the Parliament and Council that adopt them. There are three forms of 
binding legislative acts the Union (Council alone or Council and Parliament in codecision-
procedure) can pass: a regulation, which is a directly applicable law; a directive, which 
constitutes a framework of objectives which a national law must be based on to meet the 
stated aims; and a decision which applies only to a particular issue and is binding to whom it 
is addressed. Today, there are three procedures of decision-making within the European 
Union. The powers of institutions vary across them and they have changed with every treaty. 
• Codecision: This is the procedure now used for most EU law-making. In the 
codecision procedure, Parliament does not merely give its opinion: it shares 
legislative power equally with the Council. If Council and Parliament cannot agree on 
a piece of proposed legislation, it is put before a conciliation committee, composed 
of equal numbers of Council and Parliament representatives.  
                                                     
3 Foreign Affairs; Development; International Trade; Budgets; Budgetary Control; Economic and Monetary Affairs; 
Employment and Social Affairs; Environment, Public Health and Food Safety; Industry, Research and Energy; 
Internal Market and Consumer Protection; Transport and Tourism; Regional Development; Agriculture and Rural 
Development; Fisheries; Culture and Education; Legal Affairs; Civil Liberties, Justice and Home Affairs; 
Constitutional Affairs; Women’s Rights and Gender Equality; Petitions; there are 2 special committees: Financial, 
Economic and Social Crisis; Policy Challenges. 
2 Sub-Committees to the Committee on Foreign Affairs: Human Rights; Security and Defense; 
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• Consultation: The consultation procedure is used in areas such as agriculture, 
taxation and competition. Based on a proposal from the Commission, the Council 
consults Parliament, the European Economic and Social Committee and the 
Committee of the Regions. Parliament can approve the Commission proposal, reject 
it or ask for amendments. The Council examines the amended proposal and either 
adopts it or makes further amendments. In this procedure, as in all others, if the 
Council amends a Commission proposal it must do so unanimously. 
• Assent: The assent procedure means that the Council has to obtain the European 
Parliament's assent before certain very important decisions are made. The 
procedure is the same as in the case of consultation, except that Parliament cannot 
amend a proposal. The assent procedure is mostly used for agreements with other 
countries, including agreements allowing new countries to join the EU. 
Besides these three established procedures of policy making, several complementary 
(sometimes also alternative) forms of decision finding exist, some of them formal and some 
informal. On the informal side there is the increased cooperation between the European 
institutions, such as the “trilogues”, in which a few representatives of the Council, Parliament 
and Commission take part in order to resolve problems. Another example is the Open 
Method of Coordination, which was introduced in the early 2000s and in which the Member 
States can learn from each other and the tutelage of the Commission. In policy fields such as 
social policy and innovation policy a whole architecture of instruments has been developed 
in order to foster learning processes, e.g. workshops, conferences and meetings, trend 
charts comparing policies across countries and regions, exchanges of officials. At the formal 
end there are efforts to establish a Charter of Fundamental Rights in the Constitution, which 
has been ongoing for a long time but intensified in the 2000s. 
The growing independence of the Parliament is not only based on the successive changes of 
the treaties and the concomitant expanding rights of the legislative body, but also on the 
expanding services of the Parliament. Besides the services provided by the institution itself 
(e.g. constitutional, legislative, scientific), each Member of Parliament has several personal 
aides, allowing for independent information gathering and subsequent maneuvering. 
Cabinets and Bureaucracy: 
The European Commission functions “somewhere between an executive and a bureaucracy” 
(Bomberg/Stubb 2008: 46). The Commission initiates policies, ensures the correct 
application of EU policies and manages European programs. It also manages and negotiates 
international trade and cooperation agreements (Egeberg 2007: 140f). 
The Commission is divided into the College of Commissioners, which consists of 27 
Commissioners who are responsible for one or more Directorate General and the 
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administrative Commission. The administrative Commission (bureaucracy) is made up of 
various directorate generals (DGs), each of which is headed by a director-general. These 
report directly to their relevant Commissioner4. Some DGs are further split into smaller units, 
dealing with specific topics. Task forces and interdepartmental working groups can also be 
created to allow for specialization. In practice it is difficult to draw a line between the College 
of Commissioners and the administrative Commission. 
The Council proposes the Commissioners in cooperation with the president of the 
Commission, who is himself also proposed by the Council. Therefore, the College of 
Commissioners represents the composition of the member state governments regarding 
ideological orientation. 
About 330 to 400 expert committees and about 150 standing advisory groups assist the 
Commission itself in its policy making processes. These committees complement the work 
done by the Commission’s permanent staff. 
The involvement of European-level interest groups is welcomed by the Commission to 
enhance legitimacy by discussing different interests on policy ideas. The Commission 
consults groups to draw on external resources for information and to learn about support or 
resistance to its proposals (Eising 2007: 208).  
In the policy making process, the Commission has an initiative right and is then also 
responsible for the implementation of these policies.  
• Right of initiative: The Commission is responsible for initiating and drafting policies. 
Other institutions may also initiate policies, but it is up to the Commission to draft a 
legislative proposal. Regarding matters of Common Foreign and Security Policy as 
well as Police and Judicial Cooperation, the right of initiating policies is not exclusive 
to the Commission; it therefore plays a lesser role in these areas. The Commission 
is involved in almost all stages of policy making, since it also plays the role of 
mediator between the Council and European Parliament. In practice, many initiatives 
coming from the Commission are responses to pressures from other sources. The 
Commission’s ‘own initiatives’ thus account for only around 10-20 per cent of 
proposals (Bomberg/Stubb 2008:51).  
• Implementation of policies: The Commission monitors the implementation of EU 
regulation in member states. EP/Council legislation often results in broad policy 
guidelines. It is the Commission’s task to narrow these down by agreeing on more 
specific rules in the form of Commission directives and regulations, often called 
delegated legislation. 
                                                     
4 There are 22 DGs that can be seen as equivalents of national ministries or government departments.  
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EU policies are administered by the Commission as well as by national and subnational 
authorities. Various agencies have been installed in recent years in order to cope with 
exceedingly demanding EU regulation. These agencies have different functions, 
responsibilities and structures (Dehousse 1997; Kreher 1997; Krapohl 2004; 
Gehring/Krapohl 2007; Christensen/Nielsen). 
Executive-legislative Relationship: 
The relationship between the EU institutions can be described as antagonistic. In as far as 
one wants to define Council and Parliament as legislative bodies and the Commission as an 
executive body, the relationship between executive and legislative has gone through 
changes throughout the history of the EU. In the 2000s the Commission, and to a smaller 
degree the Council, has increasingly come under pressure to open up its procedures so as 
to become more transparent, especially vis-a-vis the Parliament. Since the powers of the 
Parliament have grown even faster than those of the Commission, with each successive 
treaty revision, the Commission had to make concessions to the Parliament in the last years. 
An important right of Parliament is now that it may reject a new Commission, which has led 
to lengthy negotiations between the European institutions when the Barroso II Commission 
was installed in 2009. The Parliament is quite independent nowadays and it amends most 
laws that are presented to it by the Commission. 
Party System: 
The present parliament has 736 members from all 27 EU countries, which sit in political 
groups. The largest groups are comprised of identifiable political families such as the 
European People's Party (Christian Democrats) (EPP) and the Progressive Alliance of 
Socialists and Democrats in the European Parliament S&D. Other groups are more ad hoc 
and bring together loose coalition parties. The number of seats is currently distributed as 
follows: 
• Group of the European People's Party (Christian Democrats) (EPP): 265  
• Group of the Progressive Alliance of Socialists and Democrats in the European 
Parliament (S&D): 184  
• Group of the Alliance of Liberals and Democrats for Europe (ALDE): 84  
• Group of the Greens/European Free Alliance (Greens/EFA): 55 
• European Conservatives and Reformists Group (ECR): 55 
• Confederal Group of the European United Left - Nordic Green Left(GUE/ NGL): 35 
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• Europe of Freedom and Democracy Group (EFD): 32 
• Non-attached (NA): 26 
By and large the composition of the European Parliament reflects the swings of the elections 
to the national parliaments, which by itself is notable as it shows that the elections to the 
European Parliament  are often more national than European in nature. 
Interest Group System: 
Originally the complex political system of the EU (respectively EEC, EC) included a number 
of characteristics known from corporatist systems, allowing, at least in theory, for a privileged 
access of employers’ and employees’ associations to the Commission. Especially the French 
socialist Jacques Delors, while he was head of the Commission, made an effort to 
strengthen the European Economic and Social Committee (EESC), which is an institution 
consisting of representatives of civil society (Wessels 2007, 669), but also the social partners 
themselves on the European level. 
From the early years of the EEC onwards, the second important structural element of the 
political system of the EEC/EC/EU was the existence of a multitude of access points for 
external interests, allowing for a large and indeed increasing number of interest groups. 
Several thousand of these organisations have permanent offices in Brussels and try to 
influence policy making processes. Most interest groups are sponsored by industry and 
economic interests, especially firms, have a larger weight in Brussels than those of other 
parts of civil society. 
Another type of interest representation has grown in importance since the 1980s, the 
regions. The Maastricht Treaty established the Committee of Regions, which since then has 
served as a forum of interest representation for their interests of communes and regions. 
Judicial Review: 
The European Court of Justice (ECJ) is the final arbiter in disputes among EU institutions 
and between EU institutions and member states. It pushed the integration process forward 
and, according to some scholars, its decisions contribute to the slow conversion of the 
Treaty of Rome into a constitution (Bomberg/Stubb 2008). 
Some of the ECJ’s decisions on trade have a great impact on the single market. Its rulings 
have also shaped national policies and have contributed to the claim that the Court has 
become a policy making body.  
I H S — Griessler et al. / The Challenge of Public Participation in a Multilevel System — 55 
 
Direct Democracy: 
Instruments of direct democracy have been discussed for several decades, as of now to no 
avail. In the discussions around the Charter of Fundamental Rights of the EU, the proposed 
(and failed) EU Constitution as well as the ensuing Treaty of Lisbon, instruments of direct 
democracy were discussed, with the proposals for referenda in particular becoming more 
concrete. 
Political Culture: 
For a number of years the missing demos has been decried by analysts of the EU as a key 
problem of the democratisation of the Europeanization process (Puntscher-Riekman 1998). 
This is the case not only because there are no Europe wide instruments of direct democracy 
or mass media, but, more importantly, that there is no European civil society. Most NGOs 
have their national powerbase and, at the most, a European head office in Brussels. 
Since the 1990s the European institutions have been strengthening their efforts to open up 
policy making. The Council was relatively more unsuccessful in these efforts, as were the 
Parliament and the Commission. Especially the latter would be of importance for 
strengthening civil society because it is in the early phases of the policy making processes 
that are controlled by the Commission when access to policy making at the European level is 
relatively easier than in later phases. Yet, for several reasons, amongst them the missing 
resources of civil society at the European level and established political practices favouring 
industrial interests, participation at the European level has a tendency to strengthen the 
strong (economic interests) and dilute the weak (civil society interests). Especially smaller 
NGOs therefore still have a tendency to try to influence national governments in order to 
have an impact on European policy making via the national level. 
Science-Society Relations: 
EU public health governance is increasingly focusing on the management of risk because of 
new technological possibilities and some past failures in risk governance, e.g. BSE, GMOs. 
This has lead to public mistrust and the importance of expert and stakeholder consultation 
was recognized in order to legitimize the governance process. 
From the late 1990s onwards, the EU aimed to strengthen the relationship between science 
and the public by supporting measures such as public consultation, public debates and 
public involvement in decisions about new technologies and innovation (e.g. Commission of 
the European Communities 2001). But the ways in which citizens and NGOs are involved 
remain underdeveloped (EC 2007b). Scientific expertise is very important.  
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Electoral System: 
The electoral system of the EU, i.e. for the Parliament, is proportional (since the Maastricht 
Treaty). It is however complemented by a score of national rules, e.g. on minimal threshold 
levels (mostly 4 or 5%), minimal voting age (mostly 18 and 21), the allocation of seats 
(mostly after the d’Hondt system). 
Over the course of its existence the European Parliament has tried to obtain the rights of a 
typical national parliament, including the ways of decision finding inside the institution. This 
led to a change from a strong personal mandate, in the sense of a high degree of 
independence of each Member of Parliament, to a strengthening of the European level 
parties, which was of key importance for making the institution’s means of interest 
accommodation effective and a concomitant weakening of minority rights. 
8.2 Policy Field 
Cabinets: did they have a role in the policy field for the problems handled by e.g. the 
bureaucracy? 
Though xenotransplantation policies did not involve many activities at the EU level, the 
Commission was involved in various ways, such as in the clinical trials Directive and the use 
of NHP in research. 
Legislature: did it have a role (if yes, which chamber) in the policy field for the problems 
tackled by e.g. the bureaucracy? 
The European Parliament was involved in the co-decision procedure of the clinical trials 
Directive (see 4.1) as well as Directive 2001/83/EC (see 4.2.1) and Regulation (EC) No 
1394/2007 (see 4.2.2). 
Executive-Legislative Relationship: is there a history of adversarial relations between 
executive and legislative in the policy field (e.g. over leadership on issues, media attention)? 
There are few indications of a controversy between The European Parliament, the European 
Commission and the European Council in the matter of xenotransplantation (see party 
system). 
Bureaucracy: are there specific units, which have dealt with the policy problem at hand; is 
there any cooperation with other political actors? 
Several units such as DG SANCO, DG ENV, DG03 as well as EMEA/EMA were concerned 
with the topic of xenotransplantation. 
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Judicial Review: what is the tradition of law (Common/Roman); are the courts important for 
the policy field? 
There were no court decisions in the area of xenotransplantation policies. 
Party System: were some parties represented in Parliament interested in the policy field 
(e.g. the Greens)? 
Xenotransplantation was in general hardly discussed in the European Parliament. The 
Greens posed parliamentary questions to the European Commission indicating criticism (E-
14746/96, E-4098/07). Also an S&D Member of Parliament posed a question in the context 
of using wild caught baboons (P-3227/98). In 2010, a member of the Group of the European 
People's Party asked the Commission about the progress of the XENOME project (E-
9429/2010). 
Interest Group System: were some interest groups involved in the policy field (e.g. 
pharmaceutical industry, Chamber of Commerce, professional associations)? 
Scientific experts were involved in policy making by giving scientific advice. Information 
about influence of interest groups was not available. 
Political Culture: has civil society been involved in the regulation of XTP or in similar 
problems; how open is decision-making in this policy field? 
Decision making was rather closed in the area of xenotransplantation, as it was in the area 
of human embryonic stem cell research in the context of the Sixth Framework Programme 
(Griessler 2011). 
Science-Society Relations: what is the role of scientific experts in this policy field? 
see interest group system 
Direct Democracy: were there attempts to use instruments of direct democracy in the policy 
field (e.g. petitions on GMO, BSE)? 
Letters were sent to the Commission opposing the use of NHP in research. 
Constitutional Division of Territorial Power: were some regions more active than others 
in the policy field (e.g. in the form of funding programmes, regulations)? 
n/a 
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Demand for XTP: are there interest groups asking for XTP (scientists, pharmaceutical 
industry, patient organisations etc.)? 
Scientists raised the topic as an important future issue; other scientists applied for research 
money within the Framework Programmes. 
State-EU Policy Relationship: how do EU policies enter and affect the political system 
(“download of policies”); how do national policy initiatives enter and affect the EU (“upload of 
policies”)? 
The clinical trial Directive was translated into national law by Member States. The 
EMEA/EMA guidelines are referred to in Member States. 
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